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INTRODUCTION 
A Symposium on Diabetes was presi;:nted at the 
Medical College of Virginia on September 23, 1976, 
sponsored jointly by the Division of Endocrinology 
and Metabolism of the Department of Medicine, and 
by the Department of Continuing Education. The 
symposium was also sponsored in part by a grant-
in-aid for continuing medical education from the 
Upjohn Company . 
The morning portion of the program presented 
summaries of some of the current important research 
in the field of diabetes, while the afternoon program 
was devoted to practical aspects of the treatment of 
diabetic patients. The emphasis was on the impor-
tance of achieving as good chemical control as possi-
ble, although some of the practical difficulties in 
accompanying such control are explained. We are 
grateful to the members of the MCV faculty and 
the guest faculty who presented these papers, and 
to our co-sponsors who made this program possible. 
H . ST. GEORGE TUCKER, M .D. 
Professor 
Department of Endocrinology and Metabolism 
Somatostatin: Diverse Physiological Roles 
and Therapeutic Implications* 
GORDON C. WEIR, M .D . 
Associate Professor of Medicine, Division of Endocrinology, Medical College of Virginia, Health Sciences 
Division of Virginia Commonwealth University, Richmond, Virginia 
S. BONNER WEIR , PH.D 
Research Associate, Division of Endocrinology, Medical College of Virginia, Health Sciences Division of Virginia 
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In its brief lifetime as a known peptide, soma-
tostatin has provided a truly remarkable story filled 
with surprising developments from unexpected quar-
ters. The foundation was set in 1969, when Krulich 
and McCann 1 reported that fractions of a crude hy-
pothalamic extract inhibited the secretion of growth 
hormone. In 1973, Guillemin's laboratory reported 
the sequence and synthesis of a fourteen amino acid 
peptide with the same inhibitory effect.2·3 It occurs in 
both a cyclic and linear form, each displaying equal 
biological activity. Somatostatin was assigned as its 
name, but it is also commonly referred to as growth 
hormone release inhibitory factor (G H RI F) or soma-
totropin-release inhibiting factor (SRIF). 
Characterization of somatostatin's biological ac-
tivity proceeded rapidly once the synthetic peptide 
became available. It proved to be a potent inhibitor 
of thyroid stimulating hormone (TSH).4 No effect 
was found upon prolactin or adrenocorticotropic 
hormone (ACTH) secretion except in the patholog-
ical situations of acromegaly5 and Nelson's syn-
drome,6 where inhibition has been described. The 
secretion of follicle-stimulating hormone (FSH) and 
*This paper is published with permission of Hospital Formu-
lary. Correspondence and reprint requests to Dr. Gordon C. Weir, 
Box 775, Medical College of Virginia, Richmond, Virginia 23298. 
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luteinizing hormone (LH) is not inhibited by soma-
tostatin.7 There was great surprise when investigators 
in Seattle, working with baboons, found that soma-
tostatin inhibited the secretion of two pancreatic hor-
mones, insulin and glucagon, 8 and, as studies ex-
panded to other organs, the inhibition of gastrin, 9 
secret in , 10 gastric acid and pepsin secretion, 9 and se-
cretin-stimulated exocrine pancreatic secretion 10 were 
described. Very little is known about the molecular 
mechanisms of somatostatin effects, but clues are 
being provided by the findings that inhibition of in-
sulin secretion can be partially reversed by high cal-
cium concentration 11 and by alpha adrenergic block-
ade with phentolamine.12 Furthermore, somatostatin 
appears to interfere with calcium uptake by islets 13 
and may inhibit tissue cyclic adenosine mono-
phosphate (AMP) accumulation. 14 Both events are 
thought to be important in the secretory process. 
Diabetes researchers became interested when it 
was shown that somatostatin infusions caused a fall 
of blood glucose in both normal subjects and diabet-
ics .15 In addition, somatostatin markedly slowed the 
development of ketoacidosis in insulin-deprived juve-
nile-type diabetics, 16 even though it did little to re-
verse established ketoacidosis. 17 Until then there was 
no convincing evidence that glucagon was anything 
5 
6 
more than a vestigial hormone, only continual de-
bates about the theoretical relative contributions of 
insulin and glucagon to metabolic processes. 
The widespread effects of insulin upon hepatic 
and peripheral tissues are well known, but glucagon's 
effects appear to be more limited. Although pharma-
cological amounts of glucagon can influence many 
organs, physiological concentrations act primarily on 
the liver, and probably have minor lipolytic effects on 
adipose tissue. Hepatic glycogenolysis and gluco-
neogenesis can both be stimulated by glucagon, thus 
leading to enhanced hepatic glucose output. It is also 
now clear that glucagon has a direct stimulatory ef-
fect upon hepatic ketogenesis. 18 The issue, however, is 
whether these effects are trivial and easily nullified by 
small amounts of insulin or whether they are phys-
iologically important. Somatostatin has become a 
useful pharmacological tool to help answer these 
questions, because in addition to being able to block 
insulin and glucagon secretion, it has no known di-
rect effect upon hepatic glucose output or peripheral 
glucose utilization. Several laboratories have now 
shown that the fall of blood glucose during a soma-
tostatin infusion is secondary to a reduction of he-
patic glucose output. The interpretation has therefore 
been made that inhibition of glucagon in these short-
term experiments was more important than the inhi-
bition of insulin . A similar fall in glucose was found 
in a diabetic with hypophysectomy, indicating that 
growth hormone inhibition did not have much in-
fluence.15 
These unexpected findings made it difficult to 
understand why patients with pancreatectomies were 
hyperglycemic. According to the results of the soma-
tostatin experiments, the removal of both insulin and 
glucagon surgically should have led to hypoglycemia. 
One finding used to reconcile this puzzle was that 
insulin-deprived pancreatectomized dogs have abun-
dant amounts of extra-pancreatic glucagon which is 
known to be primarily of gastric origin. 19 Humans, 
however, appear to have very little gastric glucagon.20 
The best explanation for the paradox appears to be 
that glucagon's effects are only transient; thus, a 
glucagon infusion leads to an increase of hepatic 
glucose output which lasts for about an hour.21 Sim-
ilarly, if glucagon is "removed" with somatostatin, 
there is a transient reduction in hepatic glucose out-
put.22 Therefore, during chronic somatostatin in-
fusions, a fall of blood glucose is seen before hy-
perglycemia, which appears as insulin deficiency 
dominates.22 These experiments and others have led 
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some to say that glucagon's influence on blood glu-
cose homeostasis is minor and that the hyperglycemia 
of diabetes is almost entirely secondary to insulin 
deficiency. The acceptance of a dominant role for 
insulin seems inescapable, but glucagon may still 
have important effects. Daily physiological events 
bear little relation to infusions of glucagon or soma-
tostatin; glucagon concentrations do not remain con-
stant during the day but fluctuate considerably, par-
ticularly with meals. Thus, if each one of these 
fluctuations led to a transient effect on blood glucose 
lasting for even 45 mintues, it is clear that glucagon 's 
overall influence throughout the day could be sub-
stantial. Furthermore, there is abundant evidence 
that glucagon secretion is increased in diabetes.23 To 
answer some of these critical questions, workers have 
given glucagon infusions and injections, trying to stay 
within the concentrations thought to be phys-
iologicaJ.2•- 25 There is agreement that glucagon has 
hyperglycemic effects when unopposed by insulin but 
disagreement that it causes deterioration of control 
during insulin therapy in diabetics. In addition, there . 
is growing acceptance that endogenous insulin secre-
tion in normal subjects can effectively counter the 
effects of artificially-raised plasma glucagon concen-
trations. Therefore, despite large amounts of recent 
work, there remains much disagreement about gluca-
gon's importance in diabetes. 
This rather elaborate background is necessary to 
understand somatostatin's possible usefulness as a 
therapeutic agent. Its ability to lower blood glucose is 
presumed to be mediated primarily via glucagon inhi-
bition. Therefore the question of glucagon's contri-
bution to the hyperglycemia of diabetes is of utmost 
importance. During debates about somatostatin's po-
tential in diabetes a commonly raised question is, 
"Why worry about somatostatin? Why not give more 
insulin?" Somatostatin 's advocates argue that follow-
ing each meal there is a glucagon rise which drives 
blood glucose to unacceptable postprandial peaks 
even in so-called well-controlled diabetics. Aborting 
these glucagon rises with somatostatin would there-
fore minimize glucose excursions in a way unachiev-
able with conventional insulin therapy. New data 
adding more confusion to these concepts is the find-
ing that somatostatin can impair carbohydrate ab-
sorption by the gastrointestinal tract and may lower 
postprandial glucose by a mechanism independent of 
glucagon.27 
As indicated above, much of the controversy 
about somatostatin centers on its possible effects 
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upon glucose control irt di abetes. Even though data 
showing a connection between blood glucose and 
complications is not conclusive, there is enough cir-
cumstantial evidence to warrant the pursuit of op-
timal control. Another factor linked to complications 
is growth hormone. Even though large, well-con-
trolled studies are still not available, the weight of 
evidence suggests that pituitary ablation has a benefi-
cial effect upon diabetic retinopathy. Possibly impor-
tant as well is the observation that plasma growth 
hormone levels are increased in diabetics , when con-
trol is poor28 or during exercise. 29·30 Somatostatin 
therefore may possibly benefit diabetics through two 
mechanisms-control of blood glucose and suppres-
sion of growth hormone secretion. 
Obviously much more work is needed before 
somatostatin's ultimate value as a therapeutic tool 
can be assessed and there are many hurdles which 
need to be overcome. Long-acting preparations must 
be developed , as injections before each meal are ob-
viously impractical. A protamine-zinc somatostatin 
preparation has been found to increase the duration 
of action in rats31 but has been unsuccessful in pri-
mates . There were early fears that inhibitory effects 
upon platelet function would lead to serious bleeding 
problems, but recent thorough studies have dispelled 
some of these anxieties. 32 Even though chronic sup-
pression of growth hormone might help some diabet-
ics, growth retardation in children would not be ac-
ceptable. Furthermore, it is possible that 
somatostatin's effecis on the gastrointestinal tract 
will produce discomfort and maldigestion leading to 
nutritional deficiency. Efforts are underway to de-
velop somatostatin analogues which will selectively 
suppress glucagon secretion and, although selectivity 
has not yet been accomplished, a D-tryptophan8-
somatostatin analogue has been synthesized which is 
eight times more potent than somatostatin in inhib-
iting growth hormone, insulin, and glucagon secre-
tion.33 In addition to its potential usefulness in diabe-
tes, somatostatin may be of some benefit in the 
treatment of acromegaly,5 peptic ulcer disease, and 
metastatic insulinomas and glucogonomas. 
Another area of research has focused upon the 
localization of somatostatin. lmmunohistochemical 
techniques, in particular immunofluorescence, have 
been very useful for accurate localization, and radio-
immunoassay has permitted quantitation of soma-
tostatin immunoreactivity. The major obstacle in the 
development of radioimmunoassays was the problem 
of labeling somatostatin. Labeling with 1251 of the 
7 
tyrosine of the synthetic analogue 1-tyrosinated soma-
tostatin provided the breakthrough and several very 
specific, highly sensitive assay systems have become 
available through the research of Arimura et al34 and 
by Y.C. Patel, MD and S. Reichlin, MD (unpub-
lished data, 1975). 
These techniques led to an unexpected and im-
portant discovery in late 1974 when Dubois in 
France, using immunofluorescence, found soma-
tostatin immunoreactivity in discrete cells of the islets 
of Langerhans in several species. 35 This finding was 
rapidly confirmed in isolated islets with a specific 
radioimmunoassay. 36 Somatostatin was also found 
scattered throughout the gastrointestinal tract with 
unusually large amounts in the gastric antrum, 37 and 
in addition was found in numerous extrahypotha-
lamic areas of the central nervous system, 36·38 with 
especially large concentrations in the septum and pre-
optic area, the thalamus, and the cortex. The highest 
concentration of somatostatin in the hypothalamus 
has been localized to the median eminence and the 
arcuate nucleus. 38 Definitive proof that extra-
hypothalamic material with somatostatin immuno-
reactivity is identical to hypothalamic somatostatin 
awaits amino acid sequence determination . The ma-
terial does appear to have biological activity, how-
ever, as extracts of frog pancreas with a high content 
of somatostatin immunoreactivity have been found 
to inhibit growth hormone secretion. 39 
I mmunofluorescent techniques were also used to 
show that the cells containing somatostatin immuno-
reactivity in islets and gut were of the D-type. 40 D 
cells comprise about 5% to 10% of the mammalian 
islet cell population and tend to occur in close prox-
imity to glucagon-containing A cells. In the mouse 
and rat, for instance, A and D cells form a rim of 
tissue around a central core of B cells.41 In the horse, 
however, there is a central mass of A and D cells with 
peripheral cells being B cells, and in man A and D 
cells occur together next to capillary walls. The phys-
iological importance of this distribution is as yet un-
known, but it seems likely that there is some unique 
interaction between A and D cells. 
An exception to the above pattern is found in 
birds which have a population of islets, called light 
islets, with D cells and B cells, but almost no A cells.42 
There are also, however, dark islets containing both 
A and D cells and few B cells. Birds are also unique 
because their pancreases contain high concentrations 
of glucagon and somatostatin compared to mam-
8 
mals, 43·44 but the significance of this can only be spec-
ulated upon. 
It was assumed by many that normal islet D cells 
contained gastrin, largely because the cells of gastrin-
containing tumors of the Zollinger-Ellison syndrome 
have D-cell-like morphology. Some workers have 
found gastrin immunoreactivity in islet tissue, 45 but a 
recent thorough study has been unable to confirm 
this .46 Thus, the origin of the gastrin-containing cells 
of the Zollinger-Ellison syndrome remains undiscov-
ered. 
There has been discussion about whether soma-
tostatin in extrahypothalamic cells is synthesized in 
situ or taken up following secretion by the hypothala-
mus. The latter possibility seemed less likely because 
of somatostatin's instability in blood and the finding 
that the concentration of somatostatin in islets is 
comparable to that found in the hypothalamus. Re-
cent studies in the angler fish indicate that somatosta-
tin is synthesized in islets. The angler fish is unique as 
it has enormous (100 to 200 mg) islets which can 
easily be dissected free and contain no pancreatic 
exocrine tissue. lmmunohistochemical studies have 
shown that approximately 30% of the cells contain 
somatostatin, 20% contain glucagon, and 35% con-
tain insulin. Islets were incubated with the labeled 
amino acids 3H-tryptophan and 35S-cystine, and islet 
proteins were separated with column chromatogra-
phy (P-10) and polyacrylamide gel electrophoresis 
(pH 9.5). Clear peaks of radioactivity were found in 
fractions containing the largest quantity of somato-
statin immunoreactivity. 47 Synthetic cyclic soma-
tostatin migrated into the same fractions . Thus there 
is now good evidence that somatostatin is synthesized 
in situ in islet tissue and there is also preliminary 
evidence that there is a larger precursor form of 
somatostatin (prosomatostatin ). Precursor forms 
have been described for a number of other peptides 
including insulin and glucagon . 
There is currently great interest in defining the 
characteristics of the secretory control of somatosta-
tin as this should help solve some of the puzzles about 
its physiological role. Data is fragmentary, but stud-
ies by G. Patton and co-workers48 and E. Samo ls 
and co-workers49·50 in the isolated perfused canine 
and rat pancreas now show that somatostatin secre-
tion can be stimulated by glucagon and arginine. 
The present interpretation is that glucagon probably 
has a direct influence upon the D cell, and that the 
arginine effect may be indirect, acting via local secre-
tion of glucagon by the A cell. 
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Somatostatin's contribution to the pathophy-
siology of diabetes has yet to be elucidated, but some 
provocative information is available. Following the 
induction of diabetes in rats with the B-cell toxin, 
streptozotocin, a significant increase of islet soma-
tostatin content was found using radioimmunoassay 
techniques. 51 This author has observed (unpublished 
data, 1976) that increased somatostatin in extracts of 
whole rat pancreas has been found with streptozoto-
cin, as well as with alloxan, a different B-cell toxin. 
With immunofluorescent techniques it has been pos-
sible to show both hypertrophy and hyperplasia of 
islet D cells not only in streptozotocin diabetic rats 
but also in tissue from two juvenile-type human dia-
betics.52 These findings may be a secondary phenome-
non related to the hypersecretion of glucagon, or 
perhaps the hyposecretion of insulin known to occur 
in diabetes, or to some other factor. The critical 
question is whether there is increased islet somatosta-
tin secretion leading to reduced insulin secretion. 
Also, even though diabetics secrete excessive 
amounts of glucagon which contribute to hypergly-
cemia, they might secrete even more glucagon were it 
not for D-cell secretion of somatostatin. Therefore, 
the D-cell hypertrophy could have either a beneficial 
or detrimental influence upon diabetes. 
An understanding of somatostatin's physiologic 
importance may help us make sense of what is occur-
ring in disease states. There is good reason to think 
that somatostatin's effects are exerted locally. It 
seems no accident that cells containing somatostatin 
are located in close proximity to cells capable of 
responding to somatostatin. Because of this proxim-
ity and because of somatostatin's instability in blood, 
it would seem inefficient for this peptide to be trans-
ported through the circulation to distant organs. Un-
fortunately, it has not yet been possible to measure 
physiological levels of somatostatin in plasma. Local 
secretory mechanisms are probably important in 
many organs, but islets are particularly intriguing. 
There is now good evidence that local secretion by 
autonomic nerve terminals of norepinephrine and 
acetylcholine can influence both glucagon and insulin 
secretion. 53 Some data suggest that local insulin secre-
tion suppresses glucagon release from A cells54 and 
there is now reason to suspect that glucagon may 
stimulate insulin release,55 that somatostatin may in-
hibit the secretion of insulin and glucagon, and that 
glucagon may stimulate somatostatin secretion. The 
potential interactions which take place in islet inter-
stitial spaces may be extraordinarily complex and 
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difficult to clarify. Another possible way in which 
different islet cells could communicate is through gap 
junctions. Small molecules have been shown to move 
from the cytoplasm of one cell into the cytoplasm of 
another through these structures. Gap junctions have 
been described as otcurring between B cells, and also 
between A and B cells, 56 but thorough studies of 
possible D-cell gap junctions are not yet available. 
Suggestions have also been made that there may be 
important electrical interactions between islet cells. 
Even though one can make many speculations 
about the possible importance of somatostatin in is-
lets and the gastrointestinal tract, no definitive effects 
have been elucidated. There is, however, evidence 
that somatostatin exerts a physiological influence on 
the pituitary. Injections of somatostatin antiserum 
into rats led to increases in growth hormone and TSH 
secretion, presumably by neutralizing somatostatin in 
the hypothalamic-hypophyseal portal circulation. 57 •58 
The finding that somatostatin is distributed through-
out extrahypothalamic areas of the central nervous 
system raises important questions about somatosta-
tin's possible role as a neurotransmitter. There is also 
much curiosity about the evolution and embryology 
of somatostatin, particularly since its presence is 
found in such diverse areas as the central nervous 
system, pancreatic islets, and gut. It is worth noting 
that another peptide, substance P, has recently been 
found in various parts of the brain including the 
hypothalamus, and the gut. 7 
It was predictable that a "somatostatinoma" 
would eventually be found, and 0. P. Ganda and 
associates59 indicate that it has been. A 46-year-old 
woman with an eight-year history of well-docu-
mented diabetes mellitus was found to have a pan-
creatic islet cell tumor during a cholecystectomy. 
Clinically there was no evidence of its being an in-
sulinoma, glucagonoma, or a tumor of either the 
Zollinger-Ellison or pancreati~ cholera (Verner-Mor-
rison) type. Ultrastructurally the majority of the cells 
appeared to be of the D-type. The somatostatin con-
tent of the tumor was remarkably high (301 ng/ mg of 
tissue), and the content of insulin, glucagon, gastrin, 
and vasoactive intestinal peptide was negligible. 
Pathologically the tumor was judged to be a low-
grade malignancy, and metastatic tissue was found in 
one of the 38 resected lymph nodes. Remarkably, 
following surgical removal of the entire tumor, glu-
cose values returned to normal and have remained so 
for 16 months (a recent fasting blood sugar was 73 
mg/ lOOml and two-hour postprandial was 70 
9 
mg/ IOOml ). We hypothesized that the patient was 
diabetic because of the continued secretion of large 
amounts of somatostatin by her tumor. As men-
tioned above, experimental infusions of somatostatin 
in normal subjects produce a fall of blood glucose; 
this drop, however, is only transitory, lasting for a 
few hours; with a longer infusion, hyperglycemia de-
velops. Studies of insulin, glucagon, and growth hor-
mone secretion in response to an arginine infusion 
were done prior to surgery and the response of each 
hormone appeared to be diminished, as one might 
expect with chronic somatostatin exposure. Unfortu-
nately, it was not possible to repeat the study follow-
ing surgery . When a patient is found to have an 
apparently non-functionirig pancreatic tumor of the 
islet cell type, especially if diabetes is also present, the 
possibility of a somatostatinoma shot.lid be consid-
ered . 
Somatostatin has proved to be infinitely more 
interesting than anyone might have imagined at the 
time of its discovery in 1973. Current interest in this 
unique peptide is focused upon its potential role in 
the pathophysiology and therapy of diabetes mellitus. 
It is probable that somatostatin also will come to 
occupy an increasingly prominent place in such di-
verse disciplines as cell biology, the neurosciences, 
endocrinology, and gastroenterology. 
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Insulin Receptors 
WILLIAM G. BLACKARD, M.D. 
Director, Clinical Research Unit and Chairman, Division of Endocrinology and Metabolism, Department of 
Medicine, M edica/ Co//ege of Virginia, H ea/th Sciences Division of Virginia Commonwealth University, 
Richmond, Virginia 
Much of the emphasis in the pathogenesis of 
diabetes mellitus has justifiably been placed on the 
endocrine gland, the pancreas. Extensive studies on 
the biosynthesis and release of insulin from the beta 
cell, bihormonal control of metabolism by insulin 
and glucagon, and more recently the role of soma-
tostatin have attracted the attention of students of the 
subject; but considerable evidence exists to suggest at 
least some role of tissue resistance to insulin in the 
pathogenesis of this disorder. There have been many 
advocates for extra-pancreatic factors causing dia-
betes. One of the first was Mirsky, who proposed that 
diabetes might be due to excessive amounts of hepatic 
insulinase, an enzyme which degrades insulin.' Val-
lance-Owen suggested that a circulating insulin an-
tagonist labeled synalbumin might be the cause of 
insulin resistance in diabetes.2 This factor was later 
shown to be an artifact. Others, such as Antoniades, 
proposed that insulin might circulate predominantly 
in a bound form in diabetic subjects and thus not 
exert full biologic activity.3 
The most articulate spokesman for a role of 
insulin resistance in diabetes mellitus in recent years 
has been Gerald Reavan, and his group from Stan-
ford University, who bases his theory on two obser-
vations. The first is that a large number, if not the 
majority , of adult onset diabetics have increased cir-
culating insulin concentrations rather than decreased 
concentrations as had been expected. This was first 
observed by Yalow and Berson shortly after the per-
fection of the radioimmunoassay for insulin.4 Hyper-
Correspondence and reprint requests to Dr. William G. 
Blackard, Clinical Resea rch C enter, Box 155, Medical College of 
Virginia, Richmond, Virginia 23298. 
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insulinism in diabetics has since been confirmed by 
many investigators. A second observation supporting 
the role of insulin resistance in diabetes is that of 
"glucose impedance" in diabetic patients. Glucose 
impedance was demonstrated by Reaven and col-
leagues5 by infusing glucose and insulin at a constant 
rate in diabetic and non-diabetic subjects whose en-
dogenous insulin release had been shut off by admin-
istration of epinephrine and propranolol. New steady 
states for glucose and insulin were achieved in both 
groups, with comparable insulin concentrations in 
diabetics and non-diabetics, whereas the new steady 
state glucose concentration was considerably higher 
in diabetic subjects than in non-diabetic subjects. 
These excellent studies indicated that for a given con-
centration of insulin, the blood glucose-lowering ef-
fect was less in diabetics than in non-diabetic sub-
jects. More recently, Reaven and Olefsky have 
suggested that insulin resistance in diabetic patients 
might be due to a decrease in the number of insulin 
receptors6 by showing a decrease in the number of 
insulin receptors on circulating monocytes in diabetic 
patients compared to those on monocytes of non-
diabetic subjects . Additionally, treatment of their 
diabetic subjects with an oral hypoglycemic agent 
resulted in a return to normal of the number of 
insulin receptors on peripheral monocytes.7 A thor-
ough understanding of these latter observations and 
their obvious, important implications for the patho-
genesis of diabetes requires a certain knowledge of 
the insulin receptor and of recent advances in the 
field of receptor technology. 
Properties of the insulin receptor are shown in 
Table I. As is the case with other polypeptide hor-
mones, the receptor for insulin is located on the cell 
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TABLE I 
Properties of Insulin Receptors 
A) Located on cell membrane 
B) Unevenly distributed and may occur in clumps 
C) Protein with mo! wt approx. 300,000-Tetramer con-
sisting of monomers of 75,000 mol wt each 
D) Continuous synthesis and degradation with relatively 
slow turnover rate-2%/hr 
E) Presence of insulin receptor on cell membrane requires 
protein synthesis and microfilament integrity 
membrane. Evidence for intracellular distribution of 
insulin receptors is very scant; they are not evenly 
distributed over the cell surface but rather occur ran-
domly and in clumps at times.8 Present evidence sug-
gests that the insulin receptor is a protein with mo-
lecular weight of approximately 300,000. Studies 
performed at the National Institutes of Health from 
Dr. Jesse Roth 's laboratory suggest that the insulin 
receptor is a tetramer consisting of monomers of 
75,000 dalton units each. Although the turnover rate 
is low compared to many biologic processes (2% per 
hour), continuous synthesis and degradation of the 
insulin receptor occurs. Studies with inhibitors of 
protein synthesis and microfilaments such as pur-
omycin and cytochalasin respectively indicate that 
protein synthesis and microfilarhent integrity are nec-
essary for the presence of insulin receptors on the cell 
membrane. 9 Inhibitors of microtubular function sur-
prisingly had no effect on insulin receptors. 9 
Knowledge of three concepts involving the in-
sulin receptor (Table 2) is of critical importance in 
interpreting studies in which receptor number and 
affinity have been determined. The number of recep-
tors per cell varies with the parti~ular cell being stud-
ied . However, for the peripheral monocyte, which is 
the most commonly studied cell in man because of its 
accessibility, the numbers of receptors vary between 
15 ,000 and 30,000 per cell. Clearly, only a fraction of 
the receptor sites must be occupied for biological 
activity, and the number of occupied sites required 
for the different activities of insulin may vary. For 
example, dose response data suggest that fewer sites 
must be occupied to inhibit lipolysis than to stimulate 
glucose oxidation. Thus, many of the insulin recep-
tors on the cell surface will be spare or unused recep-
tors. Recent investigations have even shown that 
some of these receptors rnay serve as a peripheral 
reservoir for insulin, · releasing intact insulin under 
appropriate circumstances. 10 
A second concept which is probably the most 
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important in understanding current receptor studies 
is that insulin inhibits insulin receptor number. Ex-
periments by Gavin et al 11 demonstrated that pre-
incubation of cultured lymphocytes with phys-
iological concentrations of insulin reduces the 
number of insulin receptors on these cells . An ob-
vious corollary of this finding would be the presence 
of decreased insulin receptors in states of hyperinsu-
linism such as obesity and some forms of diabetes . 
Although not reported yet, reduced insulin receptors 
would be anticipated in patients with islet cell tu-
mors. Thus, reduced receptor number might offer 
some protection to the patient with an islet cell tu-
mor. 
The third important concept in understanding 
insulin receptors is that of negative cooperativity. 12 
Simply stated, this concept refers to site interactions 
on the cell surf(\ce by which affinity of the receptor 
for insulin is decreased as increasing numbers of re-
ceptors are occupied. This phenomenon might also 
be considered a homeostatic mechanism which pro-
tects the individual from the effects of hyperinsulin-
1sm. 
The insulin receptor perceives and either directly 
or through a transducer substance influences the ef-
fector for a specific activity. Insulin binding is the 
first step in biological activity of the hormone. Al-
though not all receptors are required for biological 
activity, more receptors increase the likelihood of 
binding for a given concentration of insulin . Binding 
of insulin to its receptor is therefore determined by 
insulin concentration, receptor number, and receptor 
affinity. Radioimmunoassay techniques for the mea-
surement of insulin have been available for years; 
now methods are available to measure insulin recep-
tor number and affinity. 
As mentioned the most accessible cells for mea-
suring insulin receptors in vivo are peripheral mon-
TABLE 2 
Important Concepts Involving Insulin Receptors 
A) Spare receptors 
I) Number of receptors per cell va ries with cell type 
Peripheral monocytes have 15,000-30,000 receptors 
per cell 
2) Only small percentage of receptors must be occupied 
for biologic act ivity 
3) Spare receptors may serve as peripheral insulin 
reservoir 
B) Feedback inhibition of insulin receptor number by 
insulin 
C) Negative cooperativity 
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ocytes. These cells are obtained by Ficoll-Hypaque 
separation of the buffy coat of centrifuged blood. To 
determine receptor number and affinity, these cells 
are incubated with labeled insulin and increasing 
amounts of cold insulin, resulting in a binding curve 
(Fig I). Applying Scatchard analysis to this data 
results in a curvilinear plot (Fig 2B). Similar studies 
with the growth hormone receptors, or other hor-
mones not showing negative cooperativity, produce a 
linear Scatchard plot (Fig 2A ). Although th,e favored 
interpretation of the curvilinear Scatchard plot for 
insulin receptors is negative cooperativity, the possi-
bility that two types of insulin receptor sites (broken 
lines Fig 2) exist cannot be eliminated from present 
data. Employing Scatchard analysis, the number of 
receptors is calculated from the amount of bound 
insulin where the plot crosses the X axis . The slope of 
the plot reflects affinity, and new graphic analyses are 
available to express affinity even from a curvilinear 
plot.1a 
Employing these techniques, insulin receptor 
number and affinity can be determined. The factors 
influencing affinity and receptor number are shown in 
Table 3. Some of these have already been discussed. 
One of the most important determinants of affinity is 
pH; its effect on insulin binding to receptors is shown 
in Figure 3. For both human monocytes and cultured 
lymphocytes, reducing pH from 7.4 to 6.8 results in 
greatly depressed insulin binding ahd may contribute 
to the insulin resistance observed in severe diabetic 
ketoacidosis. 
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Fig !-Insulin binding to peripheral monocytes. 20 X 10' mon-
onuclear cells ( 14% monocytes) were incubated in 0.5 ml buffer 
containing 50-100 pg 125 !-insulin and increasing amounts of unla-
beled insulin to give the final concentration indicated in the figure . 
After 3 hours incubation, 200 ul aliquots were centrifuged, aspi-
rated , and the sediment counted. 
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Fig 2-Scatchard analysis of binding data. B/ F = bound/ free 
radioactive ligand. Horizontal axis (Ro) is amount of ligand bound 
to receptor in molar quantities. A. Scatchard plot for hormone not 
exhibiting negative cooperativity; B. Plot is for hormone exhibiting 
negative cooperativity or having two different receptor sites. In-
sulin receptor studies show curvilinear plot as in B. 
The major factor so far uncovered altering in-
sulin receptor number is insulin acting in a type of 
feedback mechanism to inhibit insulin receptor num-
ber. Thus, as previousiy pointed out, reduced insulin 
receptors are anticipated in obesity where insulin re-
sistance and hyperinsulinism exist. Reduced insulin 
receptors have indeed been shown to occur in obese 
humans and animals. 1•- 16 In addition, dieting and 
weight reduction result in normalization of the num-
bers of insulin receptors .13 It is debatable whether 
reduced receptor concentration is primary, resulting 
in insulin resistance and hyperinsulinism, or whether 
insulin resistance due to some other factor is primary, 
causing hyperinsulinism and, secondarily, reduced in-
sulin receptors . 
Returning to Reavan and Olefsky's observations 
in non-obese diabetic subjects,6 it is not clear whether 
the reduced insulin recej".ltor number is due to the 
hyperinsulinism exhibited by this group [fasting im· 
munoreactive insulin (IRI) 20 ± 2 versus IO ± I in 
normals] or whether it might be primary and thus be 
important pathogenetically. Nevertheless the de-
creased insulin receptors observed in the diabetic sub-
TABLE 3 
Determinants of lnslllin Binding to Tissues 
l. Receptor affinity 
PH 
Temperaiure 
Ionic strength 
Receptor occupancy (Negative cooperativity) 
II. Receptor number 
Insulin decreases receptor number 
11 l. l nsulin concentration 
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Fig 3-Effect of pH on insulin binding to receptors. Maximum 
binding refers to percent of 125 1-insµlin bound to receptors in the 
absence of unlabeled insulin. For peripheral cells 20 X IQ' , mon-
onuclear cells (14% monocytes) were used; cultured lymphoblas-
toid cells (IM-9) were used at 3.0 X 10' cells per ml concentration. 
jects in Reaven and Olefsky's study would certainly 
contribute to the insulin resistance observed. The 
return of receptor number to normal with chronic 
sulfonylurea treatment7 might in similar fashion be 
attributed to the reduced ' Insulin concentrations in 
well-controlled diabetics on chronic sulfonylurea 
therapy. 
Although the role of reduced insulin receptors in 
the pathogenesis of diabetes mellitus is equivocal, a 
rare diabetic syndrome recently reported is clearly 
related to decreased insulin receptors. 17 In several 
patients with other evidence of immunologic disease 
associated with severe insulin resistance, an antibody 
[Insulin] ng/0.5 ml 
NORMAL SUBJECT 
PATIENT 
Fig 4-1 nsulin binding to peripheral monocytes from normal sub-
ject and patient with antibodies to the insulin receptors. Details as 
for Fig I. 
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Fig 5-Effect of serum preincubation on insulin binding to cul-
tured lymphobl as toid cells (IM-9). IM-9 cells were preincubated 
with buffer , normal serum, or serum from insulin-resistant patient 
for 60 min, washed twice, and resuspended in 0.5 ml buffer at final 
concentration of 3 X 10' cells p~r ml. Binding curves were then 
obtained on these cells. 
to the insulin receptor has been demonstrated. Since 
this report we at the Medical College of Virginia have 
had the opportunity to study two patients with this 
syndrome. One of the patients requiring over 2,000 
units of insulin daily had a strongly po~itive antinu-
clear antibody as the only other manifestation of 
autoimmunity; the second patient had a scleroderma-
like illness and required 1200 units of insulin daily. 
Insulin binding curves by peripheral monocytes from 
one of these patients is shown in Figure 4. That a 
serum factor was responsible for the decreased bind-
ing was indicated by studies in which cultured lym-
phocytes (IM-9) were preincubated with the pa-
tient's sera (I : I 00) and then used for binding studies 
(Fig 5) . Scatchard analysis (Fig 6) revealed the de-
creased binding to be due to a reduction in numbers 
of insulin receptors . Studies, not shown, in which 
IM· 9 CELLS PRE INCUBATED WITH 
HEPES 
1.0 12 14 
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ng Insulin Bound/3.0xl06 cel! 
Fig 6-Sc11tchard analysis from binding data shown in Fig 5. 
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cultured lymphocytes were preincubated with IgG 
fraction of the patient's sera exhibited the same phe-
nomenon, suggesting that the serum contained an 
antibody to the insulin receptor. 
In summary, techniques are now available for 
measuring insulin receptors in vivo. So far, reduced 
insulin receptors have been observed in obese persons 
and in a selected group of adult onset diabetic pa-
tients. The pathogenetic significance of the latter ob-
servation is uncertain and may possibly be a manifes-
tation of the high insulin concentrations in these 
diabetics. However, a rare diabetic syndrome in 
which severe insulin resistance due to antibbdies to 
the insulin receptor has been reported and is now 
corroborated by our findings in two patients. 
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Why Control Diabetes? 
HAROLD RIFKIN, M.D . 
. Clinical Professor of Medicine, Albert Einstein College of Medicine, New York, New York , and Senior 
Diabetologist, Montefiore Hospital Medical Center, New York, New York 
The definition of diabetes control varies widely 
among specialists of the disease. Proponents of 
"good" control believe that the goals of appropriate 
therapy for diabetes should include an all-out effort 
to obtain levels of fasting and postprandial blood 
glucose as close to those in the non-diabetic as pos-
sible. Certainly, good control has been proven to 
accomplish the following : 
1. Prevention of ketoacidosis 
2. Prevention of severe hypoglycemia 
3. Decrease in perinatal mortality and morbid-
ity 
4. Promotion of normal growth and develop-
ment of the juvenile diabetic 
5. Prevention of, or inhibition of, infection 
The evidence that hyperglycemi~ is responsible 
for vascular complications, particularly micro-
vascular disease, and that good control will prevent 
or inhibit the rapidity of the development of this 
pathologic process, or even reverse it, is the basis of 
this presentation. · 
At the outset, however, it must be appreciated 
that retinopathy, nephropathy, neuropathy, and 
large vessel disease may be the presenting manifesta-
tions of diabetes, and that it is possible to have exten-
sive vascular complications in the presence of rela-
tively mild glucose intolerance. Furthermore, 20% of 
juvenile-onset type, ketosis-prone diabetics of more 
than 25-years duration with continuous hypergly-
cemia do not have clinically impressive retinopathy 
This is an abstract of the lecture given by Dr. Rifkin at the 
symposium, Diabetes 1976. 
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or nephropathy. Also, it has been noted that large 
vessel disease or neuropathy is absent in 20% to 40% 
of insulin-dependent diabetics . 
The evidence for good control is largely based on 
the following observations: 
1. Clinical studies 
2. Animal studies 
3. Histologic and electron microscopic data 
4. Biochemical studies 
5. Altered coagulopathy, viscosity, and hypoxia 
Recent studies in well-controlled juvenile diabet-
ics indicate that serial biopsies of quadriceps muscle 
have demonstrated "thinning" of previously thick-
ened capillary basement membrane, in contrast to 
persistent and increasing thickening of capillary base-
ment membrane in poorly controlled diabetic pa-
tients. In addition , it has recently been demonstrated 
that diabetic vascular lesions developed in normal 
kidneys transplanted into patients with diabetes mel-
litus after a period of two years, while transplanted 
kidneys in non-diabetic control patients of the same 
age and type remained unaffected; this also gives 
great support to the concept of good control. 
Animal studies with diabetic Chinese hamsters, 
mice, rats, dogs, and monkeys have indicated that 
good control with insulin therapy or islet trans-
plantation prevents or reverses lesions in the eyes, 
kidneys, or nerves. 
Histologic and electron microscopic studies of 
capillary basement membrane of muscle have given 
conflicting results. One group of observers indicates 
that basement thickening is already genetically pre-
determined, while other investigators relate capillary 
basement membrane thickening to the duration of 
diabetes. Methodology of technique, the patient' s 
age, unknown duration of existing diabetes, and cri-
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teria for the diagnosis of diabetes have to be clarified 
before coming to definitive conclusions. 
Biochemical studies indicate that hyperglycemia 
or insulin deficiency produces alteration in vascular 
basement membrane composition, as well as accumu-
lation of glucose-derived substances, such as sorbitol 
in the lens of the eye, Schwann' s cell, and aorta. 
Recently, an elevation of glycolysated hemoglobin 
(HbAJc) has been noted in the blood of diabetic mice 
as well as human diabetics . The glycolysation of he-
moglobin appears to be a post-synthetic modification 
of HbA which is dependent on the degree and dura-
tion of hyperglycemia. 
Recent data reveal that platelet aggregation is 
more intense in diabetic patients, with increased sen-
sitivity of platelets to aggregation from adenosine 
diphosphate (ADP) and epinephrine. This sensitivity 
correlates with elevated levels of Von Willebrand fac-
tor, which in turn appears to be influenced by growth 
hormone. Also, platelets from diabetic subjects are 
more sensitive to arachidonic acid-induced aggrega-
tion, which can be abolished by aspirin, which is a 
prostoglandin synthetase-inhibitor. 
Spontaneous fibrinolytic activity of the blood is 
abnormally low in persons with diabetes mellitus, 
and implies a poor defense mechanism against fibrin 
deposits in the vessel walls, which conceivably may 
contribute to the development of diabetic micro-
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angiopathy. Increased red blood cell aggregation and 
alterations in plasma protein changes in diabetics, 
with their effects on blood viscosity and flow , may 
also play a role in accelerating the rate of progression 
of diabetic microangiopathy. 
In addition, the decreased reactivity of HbAlc 
with 2,3 diphosphoglycerate might impair oxygen un-
loading in diabetes, and contribute to tissue hypoxia, 
which may have pathogenetic implications in the de-
velopment of diabetic angiopathy. 
Whether reversal of hyperglycemia, as well as 
the use of agents to inhibit some of the above-de-
scribed adverse effects of the diabetic milieu, may 
affect the development of diabetic microangiopathy is 
far from settled. Consideration must be given to more 
intense regulation of dietary factors; use of the newer 
oral hypoglycemic agents; administration of insulin 
three or four times daily for better control; long-term 
studies on the use of aspirin, and other platelet-aggre-
gating inhibitors, as well as phosphate supplements; 
availability and effectiveness of growth hormone in-
hibiting agents; the use of substances which can inter-
fere with the post-ribosomal steps of basement mem-
brane assembly; and finally , improvements in the 
delivery of insulin, whether it be by better biome-
chanical engineering or by increased knowledge of 
immunologic and other biologic defenses in the use of 
islet or organ transplantation. 
Insulin Treatment of Diabetes Mellitus 
H. ST. GEORGE TUCKER, M.D. 
Division of Endocrinology, Department of Medicine, Medical College of Virginia, Health Sciences Division of 
Virginia Commonwealth University, Richmond, Virginia 
Dr. Harold Rifkin*, has previously set forth the 
reasons why we should try to keep the diabetic pa-
tient's blood sugar as near normal as possible. What 
are the generally accepted standards of good diabetic 
control? 
Marble1 considered control of the insulin-depen-
dent diabetic good if the whole blood glucose before 
meals was not over 130 mg% ( = serum glucose 150 
mg%), the 24-hour urinary glucose did not exceed 5% 
of the carbohydrate intake, and there was no keto-
nuria; Oakley et al2 defined satisfactory control as 
blood glucose before meals of less than 150 mg% with 
no hypoglycemia; Lewis et al, 3 in a recent paper 
dealing with pregnant diabetics, recommended fast-
ing blood glucose below 100 mg% and blood glucose 
two hours after break fast below 160 mg%. 
In some diabetics we can accomplish this type of 
control; in others we cannot. The maturity onset 
diabetic has some endogenous insulin under auto-
regulatory feedback control and, with a judicious diet 
or with the addition of a sulfonylurea drug or some 
exogenous insulin, near normal blood sugars can be 
achieved. However, in the juvenile or young adult 
onset diabetic, with little or no endogenous insulin, it 
is very difficult, even with complicated schedules of 
administration of insulin, to get blood sugars any-
where near normal without producing hypoglycemia. 
A reasonable goal for every diabetic would be to 
maintain blood sugars as near normal as possible 
without producing hypoglycemia and without requir-
ing a program so restrictive that it interferes with the 
quality of life. 
* see preceding abstract. 
Correspondence and reprint requests to Dr. H . St. George 
Tucker, Division of Endocrinology, Box l l l , Medical College of 
Virginia , Richmond, Virginia 23298. 
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Figure l, taken from a paper by Molnar et al, 4 
illustrates the daily variations in plasma insulin and 
blood glucose throughout a 24-hour period in a nor-
mal individual. Meals, snacks, and standard exercise 
periods are indicated. It is apparent that each feeding 
is accompanied by a sharp peak in insulin secretion 
which brings about disposal of ingested glucose and 
amino acids, and limits the blood sugar rise. 
It is obvious that no one injection of inter-
mediate-acting insulin can in any way duplicate the 
normal insulin pattern. At best an injection ofNPH® 
or Lente® Insulin given before breakfast will be ab-
sorbed for the most part over the next 8 to 12 hours 
when meals will be eaten, with some carry-over effect 
during the night. As diabeticians we hope to accom-
plish blood sugar levels that average ;;omewhere near 
normal, but obviously the blood sugar will rise too 
high after meals and .may fall too low before the next 
meal. Further leveling out may be accomplished by 
the addition of between-meal and bedtime snacks. 
We always insist on midafternoon and bedtime 
snacks in every patient on NPH® or Lente® Insulin. 
Bressler and Galloway5 some years ago called 
attention to variations in the timing of effect of vari-
ous insulins (Fig 2). Diabetics were divided into those 
showing a normal (B) response, a transient (A) re-
sponse, or a delayed (C) response to NPH® or Lente® 
Insulin . Those with a normal response could be mod-
erately well regulated with a single morning injection 
of NPH® or Lente® Insulin . Those with a transient 
response might benefit from a second small dose of 
NPH® or Lente® Insulin before supper, and those 
with a delayed response might require the addition of 
regular insulin to the morning dose of NPH® or 
Lente® Insulin . The reasons for this variation in the 
timing of effect of the intermediate-acting insulins is 
not known . One possible factor delaying the action of 
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Fig I-Meal-to-meal <ind day-to-day variations in blood glucose 
and immunoreactive insulin in a normal subject on two successive 
days (solid line represents first day; interrupted line represents 
second day). B = breakfast, L = lunch, Sk = snack, D = dinner, 
Su = supper, E = exercise, one hour of walking. 
insulin is its binding to antibodies, with subsequent 
release, which prolongs the insulin effect. 
Lukens, 6 Forsham, 7 and others pointed out some 
time ago that multiple injections of regular insulin 
before meals, perhaps accompanied by one or more 
injections of longer-acting insulin to control over-
night blood sugar, would more closely resemble nor-
mal physiology and would be likely to give better 
control than a single injection of long- or inter-
mediate-acting insulin. Indeed it is doubtful whether 
the medical profession did diabetic patients any favor 
when some years ago it abandoned multiple insulin 
injections in favor of the once-a-day injection of 
longer-acting preparations. Once the diabetic public 
became accustomed to the single morning injection it 
was difficult to persuade patients to go back to mul-
tiple injections and, by and large, doctors hav~ sel-
dom made the effort. 
Recently there has been a renewal of interest in 
the use of multiple injections of regular insulin to 
accomplish more physiologic control, especially since 
reports from Paris by Job et a1 8 seem to indicate that 
such regimens in juvenile diabetics result in better 
control and in less progression of retinopathy . Also, 
especially good control in pregnant diabetics with 
multiple injections appears to result in lower infant 
mortality and morbidity, 3 although better obstetrical 
techniques for monitoring the pregnancy and timing 
of delivery are equally important factors in the im-
proved outcome in these patiepts. Thus a number of 
schedules of insulin administration have been pro-
posed as illustrated in Table 1. There is good ration-
ale for each of these programs in a given situation, 
although it is unlikely that any one type of progra m 
will be best for all patients. 
Attempts have been made to define complicated 
dosage schedules even more rigidly. Lewis et al3 rec-
ommend the following formula for insulin adminis-
tration for pregnant diabetics: 
Morning NPH® 
Morning reg. ins. 2: I 
Evening NPH® 
Evening reg. ins. = I : I 
Morning total = 2 X evening total 
I have tried this schedule with several pregnant dia-
betics with quite varied results. I think the reasoning 
is right, but it should be remembered that no two 
diabetic patients will respond in exactly the same 
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Fig 2-Blood sugar responses to a single daily dose of NPH® 
Insulin. 
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TABLE I 
Various Schedules for Insulin Administration 
Afternoon Bedtime 
Breakfast Lunch Snack Supper Snack 
N 
R + N 
N 
R 
R 
R +N 
R 
R 
N 
N 
R +N 
R+N 
(N = _NPH'" or Lente"' Insulin. R = regular or crystalline 
zinc insulin.) 
way-there are just too many variables. Some of 
these are listed in Table 2. 
How then should one approach if)sulin treat-
ment in any given patient? Two basic principles are 
helpful: (I) analyze what kind of diabetic the patient 
is, and (2) keep the variables at a minimum. 
The first principle means to try to form some 
idea of how much endogenous insulin the patient has 
from evaluation of the age of onset of the diabetes, 
his or her weight at onset, and the severity of symp-
toms at onset, especially weight loss. Onset of diabe-
tes early in life, severe polyuria and polydipsia, and 
especially weight loss from uncontrolled diabetes, 
usually indicate total or near total insulin deficiency. 
If the patient has been on treatment, the diabetician 
should also consider the occurrence of ketoacidosis 
TABLE 2 
Variable Factors Limiting Good Blood Sugar Control 
with Exogenous Insulin 
I. Variations in food intake 
2. Variations in exercise 
3. Emotional factors and other stresses 
4. Factors affecting the avai lability and effectiveness of 
administered insulin: 
(a) variab le absorption rates from injection site 
(b) variable antibody titers and uncertain rates of release 
of insulin from antibodies 
(c) variations in receptor binding sites and in their 
affinity for insulin 
5. Variations in glucagon secretion 
6. Hypoglycemia with rebound hyperglycemia caused by 
counter-regulatory factors 
7. Exogenous insulin is delivered into systemic circulation 
and not primarily into portal circulation and to the liver 
as is endogenously secreted insulin 
or frequent hypoglycemic reactions, both of which 
suggest that the patient has little or no endogenous 
insulin. If the patient has been controlled in the past 
on oral agents he or she must have had some endog-
enous insulin at that time. 
The second principle, keeping the variables at a 
minimum, means trying to get the patient to maintain 
reasonably constant eating habits and exercise pat-
terns as well as simplifying the insulin schedule until 
the need for multiple doses becomes apparent. In 
general, begin with a single dose of NPH® or Lente® 
Insulin every morning, perhaps 20 units if the patient 
has never before taken insulin. Instruct the patient in 
a proper diet, which probably should include both 
afternoon and evening snacks, for his or her weight 
and activity . The patient may continue working but 
should test his or her urine four times daily, before 
meals and at bedtime. If the patient continues to spill 
sugar, increase the insulin by 5 units every four or five 
days until some negative urine tests are obtained. 
Check the blood sugar at the time of the negative 
urine test, and if this is still high, continue to increase 
the insulin until the blood sugar is in the desired 
range. If any hypoglycemic reactions occur, the in-
sulin dose should be reduced . As the patient ap-
proaches control the urine tests should be determined 
from second voidings whenever the first voiding con-
tains sugar. 
Many diabetics will come under satisfactory 
control with a single morning dose of NPH® or 
Lente@ Insulin. If glycosuria or hyperglycemia per-
sists before breakfast, with negative tests in the after-
noon, the patient may be classified as a transient 
responder, and a second small dose of N PH® or 
Lente''9 Insulin should be added before supper. If the 
morning test is repeatedly negative but glycosuria 
persists before lunch, the patient may be a delayed 
responder, and regular insulin can be added to the 
morning NPH@. 
If the desired degree of control is not achieved by 
these measures, both regular and NPH® Insulin may 
be given twice daily. In general the indications for 
administration of such multiple doses would follow a 
schedule such as in Table 3, as suggested by Oakley et 
al.2 
In a highly reliable and highly motivated patient, 
such as a pregnant diabetic, this type of program may 
succeed ; or a highly obsessive patient may religiously 
seek perfect i:.;ontrol. Unfortunately most patients are 
not so reliable, and the obsessive ones usually end up 
making themselves hypoglycemic. 
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TABLE 3 
Management of the Severe Diabetic with Twice Daily 
Injections of Re~ular and NPH® Insulin 
Timing of urine or 
Peridd of bldod sugar for 
Insulin Maximum Action dose adjustment 
Morning RI Breakfast to lunch Pre-lunch 
Morning NPH® Lunch to supper Pre-supper 
Evening RI Supper to midnight Bedtime 
Evening NPH '"' Midnight to breakfast Pre-breakfast 
What do you do with the patient who never 
shows any consistent pattern? You look for such 
variables as food intake, exercise, emotional upsets, 
and other factors . Hypoglycemia, recognized or un-
recognized, is the cause of much brittleness. For ev-
ery recognized hypoglycemic reaction, the brittle 
juvenile diabetic has ten other occasions when the 
blood sugar is quite low without his knowledge, and 
each may be followed by rebound hyperglycemia. 
You must learn to recognize this pattern and to re-
duce insulin accordingly. Tables 4 and 5 illustrate two 
such patients. 
Table 4 is a record of the urine sugars on a 23-
year-old dental student with diabetes of two years' 
duration, during which he took 12 units of Semi-
lente® and 20 units of Lente® Insulin daily. He was on 
a 2500-calorie diet including three main meals and 
midafternoon and bedtime snacks. He was extremely 
conscientious and liked to keep all his urine tests 
negative. To keep himself in physical trim he ran two 
TABLE 4 
Insulin Dosage and Urine Tests Showing Glycosuria 
Following Asymptomatic and Unrecognized Hypoglycemia 
J.S. (Male, 23) Urine sugars 
Insulin 7 II 4 9 
12 SL ± 20 L N N N N 
N N N N* 
4 + 4+ N N 
N N N N* 
2+ 3+ N N 
N 3+ N N* 
3+ N N 4 + 
4 + I+ N N 
N N N N 
* Ran approximately 2 miles 
(SL = Semilente"' Insulin. L = Lente® Insulin .) 
miles several times a week, and because of his busy 
schedule chose the late evening as the time for his 
exercise. He was not conscious of any hypoglycemic 
reactions, but he invariably showed unexpected sugar 
in his urine on the mornings after running; when he 
had not run the night before, his tests were almost all 
negative. It became apparent that the additional exer-
cise was causing undetected hypoglycemia during the 
night, followed by rebound hyperglycemia and glyco-
sufia the next day, the so-called Somogyi effect 
caused by the secretion of epinephrine, glucagon, cor-
tisol, and growth hormone in response to hypogly-
cemia. The situation was corrected by insisting that 
he take sizable extra feedings just before and just 
after his nocturnal exercise periods; this prevented 
the hypoglycemia and its consequent rebound. 
The Somogyi rebound hyperglycemia following 
hypoglycemia is most often seen in the brittle juvenile 
diabetic, but can be observed in any insulin-depen-
dent diabetic. Table 5 shows the record of urine tests 
on a 72-year-old diabetic taking 32 units of NPH® 
Insulin daily. He also was very conscientious and 
very careful about his diet. After a series of days with 
all negative urine tests, he showed unexpected 4+ 
sugar at noon on Aug 29 and Aug 30, with sugar 
TABLE 5 
Insulin Dosage and Urine Tests in an Older Diabetic 
Showing Glycosuria, Probably Representing Rebound 
After Unrecognized Hypoglycemia 
J.Y.C. (Male, 72) 
NPH"' 7 12 5 9 
8/ 27 32 N N N 4 + 
8/ 28 N N N N 
8/ 29 N 4+ I + 3+ 
8/ 30 N 4 + 4 + 4 + 
8/ 31 30 N N N N 
9/ 1 N tr tr N 
9/ 2 N N 3+ 3+ 
9/ 3 tr tr N 4 + 
9/ 4 N N N N 
9/ 5 N N N N 
9/ 6 N N N N 
9/7 N N N N 
9/ 8 N tr tr 4 + 
9/ 9 N 2+ N 3+ 
9/ 10 3+ 3+ N 4 + 
9/ 11 N 2+ 4 + 4 + 
9/ 12 3+ tr N N 
9/ 13 I + 3+ N N 
9/ 14 N N N N 
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persisting during the rest of the day. Questioning 
revealed no dietary indiscretions, no variation in ex-
ercise, and no emotional upsets or other stresses to 
account for the glycosuria. Although he was unaware 
of any hypoglycemic symptoms, it seemed inconceiv-
able that the dose of insulin which had kept his tests 
all negative over the previous days could be so in-
adequate on these days. I suspected unrecognized 
hypoglycemia and reduced his NPH® Insulin to 30 
units. The urine tests improved and remained all 
negative until Sep 8 when he again began to show 
sugar in the evening test. Not shown in Table 5 is the 
fact that his NPH® Insulin was lowered again to 28 
units and later to 26 units with improvement each 
time and, finally, all negative urine tests. He remained 
on 26 units of NPH® for several months, then began 
to spill sugar in all specimens; the NPH® Insulin dose 
has been gradually raised again to 30 units with good 
control. The reason for these swings in insulin re-
quirement over periods of several months is un-
known. Some patients go through cycles when their 
insulin requirement goes up or down for no apparent 
reason; these may be over months or over shorter 
periods. All we can do is to try to keep pace through 
adjustments in insulin dose. 
When the patient alternates between good days 
and bad days, with lots of sugar or no sugar, suspect 
hypoglycemia with rebound. In any event you should 
adjust the patient's insulin dose to his or her better 
days and not try to give more for the bad days or you 
will surely produce hypoglycemia. 
The bane of the diabetician 's existence is the 
obese patient on insulin. If these patients could have 
been made to reduce in the beginning, many of them 
would not have needed insulin. Once on insulin, li-
polysis is inhibited, weight reduction becomes even 
more difficult, and these patients tend to gain more 
weight which increases insulin resistance, creating a 
vicious circle of upward spiraling weight and insulin 
dosage. In this instance it may be better to cut back 
the insulin dosage and let the patient spill sugar until 
somehow he or she can be persuaded to really limit 
food intake. There is no satisfactory answer to this 
problem unless the patient loses weight. 
In summary, I believe in aiming for the best 
possible control for each patient through an empir-
ical approach which seeks to arrive at the best sched-
ule for the individual patient. We want especially 
tight control for the pregnant diabetic, and for this 
patient it is likely that multiple insulin injections are 
needed . If further experience confirms the benefits of 
multiple injections for juvenile patients, this type of 
treatment may a1so be indicated for these patients. 
Figure 1 is reproduced with permission from Mayo Clinic 
Proceedings (47:709-719, 1972). 
Figure 2 is reproduced with permission from Medical Clinics 
of North America (55:861-868, 1971 ). 
Table 3 is reproduced with permission from Diabetes 
( 15 :2 19-222, 1966). 
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Oral Hypoglycemic Agents 
HAROLD RIFKIN, M.D. 
Clinical Professor of Medicine, Albert Einstein College of Medicine, New York, · New York, and Senior 
Diabetologist, Montefiore Hospital Medical Center, New York, New York 
The pharmacology of the two general groups of 
oral anti-diabetic agents, namely the sulfonylureas 
and biguanides, are briefly discussed here. The sul-
fonylureas have a common hypoglycemic core. These 
sulfonylurea compounds can be divided into short, 
intermediate, and long-acting agents, with varying 
half-lives, and duration of action. Therapeutic doses 
of sulfonylureas have produced wide variations in 
serum levels depending upon the rates of absorption, 
rates of metabolism, renal clearance, and degree of 
protein-binding. Tolbutamide is a short-acting agent 
metabolized by the liver to inactive compounds 
which are excreted by the kidney; it has a half-life of 
four to five hours, a duration of action of approxi-
mately six to ten hours, and is given in divided daily 
dosage. Acetohexamide and tolazamide, the inter-
mediate-acting compounds, are metabolized by the 
liver. Approximately 75% of acetohexamide is me-
tabolized to another hypoglycemic compound, and 
tolazamide is metabolized to several hypoglycemic 
products. The duration of the action of these agents is 
approximately 10 to 16 hours; they are administered 
either once or twice daily . Chlorpropamide is only 
slightly altered, less than l % being metabolized, 
probably in the liver; it is firmly bound to protein, is 
dependent on renal excretion for clearance, and, as it 
has a duration of action varying from 35 to 72 hours, 
it is given only once daily. 
Sulfonylurea compounds appear to exert their 
primary action through direct stimulation of pan-
creatic insulin secretion. Peripheral insulin levels cor-
relate with blood sugar levels during acute therapy, 
This is an abstract of the lecture given by Dr. Rifkin at the 
symposium, Diabetes 1976. 
Correspondence and reprint requests to Dr. Harold Rifkin, 
Montefiore Hospital Medical Center, Bronx, New York 10467. 
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but do not appear to correlate with blood sugar-
lowering effect of chronic drug therapy. Hence, im-
portant extra-pancreatic actions may be responsible 
for the hypoglycemic effects of these compounds, that 
is, induced hepatic glycolytic enzymes, impaired in-
sulin sensitivity, increased membrane receptors, 
lowered insulin resistance, or other as yet undefined 
mechanisms. 
Phenformin, a biguanide, is metabolized to some 
extent by the liver, but approximately 65% may be 
excreted unchanged by the kidneys. The hypogly-
cemic effect of the "short-acting" tablet lasts six to 
eight hours. In contrast, the timed disintegration cap-
sule has a duration of action from 8 to 14 hours 
because of prolonged gastrointestinal absorption of 
the drug. The mode of action of these agents is not 
completely understood. There is evidence that phen-
formin lowers blood sugar levels by accelerating ane-
robic glycolysis and delays the absorption of glucose 
from the gastrointestinal tract. Phenformin also de-
creases hepatic gluconeogenesis of diabetic animals, 
but this has not been confirmed in man. It is also 
quite possible that the anorexigenic effects of this 
agent may lower caloric intake, and help exert its 
hypoglycemic action in this manner . 
Side effects and toxic effects are relatively rare 
with the sulfonylureas. Hematologic, hepatic, and 
dermatologic reactions have been described. An "an-
tabuse" effect has been noted with chlorpropamide. 
Rare cases of hypersensitivity angiitis have been de-
scribed. Dilutional hyponatremia has been noted 
with chlorpropamide, and very occasionally with tol-
butamide. In contradistinction, tolazamide and 
acetohexamide appear to have a proximal tubular 
diuretic effect. 
Side effects of phenformin consist primarily of 
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gastrointestinal reactions. Lactic acidosis, however, is 
a serious problem, particularly in the phenformin-
treated diabetic with liver or renal disease, who is 
vulnerable to a variety of medical conditions which 
may lead to tissue hypoxia, that is, myocardial in-
farction, peripheral vascular disease with gangrene, 
and gastrointestinal bleeding. In addition, alcohol 
and phenformin are a particularly dangerous combi-
nation. 
There are a number of drugs which may interact 
and potentiate the effects of the sulfonylurea com-
pounds. These include phenylbutazorie, probenecid, 
alcohol, salicylates, and monamine oxidase inhib-
itors. The list is growing, and the clinician treating 
the diabetic with sulfonylureas must be constantly on 
the alert. 
The indications for oral agent therapy are rela-
tive, depending upon the patient's age, weight, fasting 
and postprandial blood sugar levels, and intensity of 
symptoms. Oral agents have a place in the manage-
ment of the maturity onset diabetic. The aim of ther-
apy of the diabetic patient is to produce normal 
weight for frame and height, to obtain as close to 
normal fasting and postprandial blood glucose levels 
as possible, to maintain normal lipid levels, and to 
keep the patient free from hypoglycemic episodes. 
Diet or insulin therapy or both are the bases of treat-
ment for the non-obese patient with fasting bfood 
glucose values above 160 mg/ JOO ml. A weight reduc-
tion regimen, however, is the mainstay of management 
of the obese maturity onset diabetic. This requires 
constant dietary counseling by the physician, the 
dietician, and the nurse-educator. In most cases, if 
weight reduction is successful, plasma glucose and 
lipid levels will approach normal values, and the pa-
tient will usually become asymptomatic. If the plasma 
glucose still remains high, and particularly if the patient 
is still symptomatic, the sulfonylurea agents may be 
tried. If hyperglycemia is not controlled within a short 
period of time, by either short- or intermediate-acting 
agents, as well as long-acting sulfonylurea com-
pounds, then insulin should be administered; the 
"uncontrolled" patient may also have been taking 
other drugs during this period which may antagonize 
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the action of the oral agents, for example, corticoste-
roids in pharmacologic doses, excessive doses of thy-
roid hormones, diuretics which may produce moder-
ate to severe hypokalemia, oral contraceptives, and 
nicotinic acid in pharmacologic doses. More signifi-
cantly, the patient must be warned against increasing 
weight gain during the administration of these oral 
agents. All these factors must be borne in mind in the 
consideration of "secondary failures. " Hypoglycemia 
during oral therapy may result from overdosage (that 
is, failure to titrate dosage downward), poor choice 
of the oral therapeutic agent, omission of meals, renal 
or hepatic insufficiency, and interaction with other 
drugs, or alcohol. 
In conclusion, comment is made on the findings 
of the University Group Diabetes Program (UGDP). 
The purpose of the UGDP was to determine whether 
or not control of blood glucose levels would help to 
prevent or delay vascular disease in non-insulin-re-
quiring diabetics. After 81/2 years of follow-up at 12 
university-affiliated treatment centers, "The findings 
of the study indicate that the combination of diet and 
tolbutamide therapy is no more effective than diet 
alone in prolonging life. Moreover, the findings sug-
gest that tolbutamide and diet may be less effective 
than diet alone or diet and insulin, at least insofar as 
cardiovascular mortality is concerned." The debate 
on the validity of this study still rages . A number of 
the criticisms leveled against the study by diabetolog-
ists, other clinicians, epidemiologists, and statisti-
cians are discussed. These include inappropriate pa-
tient selection and randomization, higher risk factors 
at the outset of the study, manipulation of elec-
trocardiographic data, risk factors such as smoking 
and hypertension not measured or monitored, use of 
fixed dosage of drug, clinic preponderance regarding 
mortality (it has been alleged that the bulk of tolbuta-
mide mortality occurred in four clinics, Birmingham, 
Boston, Cincinnati, and Minneapolis), use of "pa-
tient data" against "computerized data," neglect of 
appropriate "vascular" history, neglect of "co-mor-
bidity," contradictory clinical studies here and 
abroad, and the danger of extrapolation of the 
UGDP findings to other sulfonylurea agents. 
Diabetes in Children and Adolescents; 
Observations on Diabetic Microangiopathy 
ELSA PROEHL PAULSEN, M.D. 
Associate Professor of Pediatrics, University of Virginia School of Medicine, Charlottesville, Virginia 
You may well wonder why I have combined a 
talk on diabetes in children and adolescents with one 
on diabetic microangiopathy when as pediatricians 
we rarely, if ever, see clinical evidence of the seql!elae 
of vascular disease in our patients. If we see protein-
uria in a child, we seek another cause. We may see 
young teen-agers with a microaneurysm or a trace of 
protein, but we soon refer them to our internist 
friends who fall heir to the care of problems that 
doubtless have their beginning in childhood years . 
Pediatricians are, therefore, concerned about these 
problems and the adequ acy of treatment they are 
prescribing for their young diabetic patients. 
There is a recent movement to place consid-
erable emphasis again on strict control of blood glu-
cose as a means of reducing complications of diabe-
tes. In an effort to achieve better control rnany 
physicians are placing their patie11ts on two injections 
a day. 
I believe we can say that there are few, if any, 
physicians today who could duplicate Dr. Elliott P. 
Joslin's success in obtaining patient cooperation in 
his efforts to control their diabetes. Yet data from his 
clinic show that only a small percentage achieved 
what he considered excellent control. Nqr did we see 
a striking difference in the incidence of complications 
in his patients when compared with that in the gen-
eral diabetic population. 
I do not minimize the need for achieving as 
nearly optimal control as one can with insulin , but I 
believe a return to the old emphasis on strict control 
Correspondence and reprint requests to Dr. Elsa P. Paulsen , 
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does a disservice to our diabetic children and adoles-
cents . It misleads them into thinking that controlling 
the blood sugar adequately is possible with present 
day methods of insulin administration; that if this is 
achieved, it will prevent or slow down complications; 
and that if this is not achieved, even with the most 
conscientious efforts, it is the patient's fault. I believe 
there is evidence that none of the above is true. A )so, 
this re-emphasis on <;.:ontrol and what it does or does 
not do to the basement membrane, diverts our atten-
tion from pursuing other productive avenues of re-
search that may uncover clues and therapeutic ap-
proaches. It is with some of these avenues that I 
would like to acquaint you and stir your interest. 
I would like first to address myself to important 
considerations in the care of the child or adolescent 
who has diabetes . 
It is , of course, fundamental that the patient and 
the parents be properly educated about diabetes and 
its control at the very beginning if one is to expect 
acceptance and participation in a program of good 
management. We feel this should always be initiated 
on a hospital ward even if the child is not acidotic. 
Here the patient and parents can work with a teach-
ing team in a relaxed setting where questions can 
readily be answered before the family is left on its 
own. The focus of instruction for the very young 
child and infant is both parents; by 7 to 10 years of 
age the child can help with urine testing; the 11-year-
old can learn to give his or her own injections. In the 
teens the patient becomes the focus of instruction 
with parents also learning the facts and techniques. 
Do not be misled on this point: teen-agers very much 
need and want the support of their parents in these 
circurnstances. 
As soon as the patient has intravenous feedings 
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discontinued and is ambulatory the routine that he or 
she will continue at home is initiated. After the acid-
osis is cleared the patient is not awakened during the 
night hours for either urine testing or supplemental 
insulin. 
The educational process continues upon dis-
charge from the hospital, first with phone calls to talk 
over changes in insulin dosage, and then in weekly 
visits to the clinic. As confidence and understanding 
increase, visits are less frequent but are continued 
with regularity. 
What do we teach our patients about diabetes 
and how it should be managed? 
Good management of the diabetic begins with 
the physician's smooth management of the initial ke-
toacidotic episode, for actions speak louder than 
words. I believe pediatricians have an advantage here 
because it can be said with certainty, if not with 
modesty, that pediatricians have been in the forefront 
in the proper administration of fluids and electrolytes. 
One need only recall the names of Gamble, Butler, 
and Darrow to know that we have had good mentors. 
Fluids play a most important role in recovery from 
acidosis; no amount of insulin will rid the patient of 
the accumulation of hydrogen ion and restore his or 
her base deficit. Briefly, the initial hydrating solution 
is a mildly hypotonic solution of sodium chloride free 
of potassium, containing bicarbonate if acidosis war-
rants its use. This is followed by a more hypotonic 
solution including potassium and dextrose, usually 
around the second hour. We discourage the use of 
isotonic saline as unphysiologic because of its high 
anion concentration and the absence of free water. 
Pediatricians also for many years have been adminis-
tering small doses of insulin at frequent intervals 
instead of the large doses prescribed in adults. In-
deed, the recent introduction of continuous in-
travenous administration of low levels of insulin has 
little if any advantage over our long-used methods of 
administration. We begin with 0.5 to 1.0 units/ kg 
crystalline insulin, giving half intravenously and half 
deep subcutaneously, Every hour the dose is reduced 
by 50% unless the interval reveals no progress in 
reducing the blood glucose. The previous hour' s dose 
is then repeated. 
After intravenous therapy is discontinued and 
oral feedings initiated, regular insulin is given with 
meals for one or two days. Lente®, a long-acting 
insulin, comprised of 70% Ultralente® and of 30% 
Semilente®, is then given once daily prior to break-
fast. 
Our goal is to allow a trace or 1 + glycosuria in 
urines tested prior to meals and at bedtime. The 
Lente® is increased daily by 2 to 4 units until control 
is achieved. 
We teach the patient to monitor his or her dia-
betic control through daily urine tests: that is, a 
double-voided specimen before breakfast, before sup-
per, and at bedtime. After discharge from the hospi-
tal we allow time for a pattern to develop in response 
to the child's home and school routine. If the glyco-
suria falls to negative levels after discharge as so 
frequently happens, the patient reduces the Lente® 
Insulin by 2 units after a day of negative tests, or by 4 
units if there are symptoms as well. If glycosuria 
increases uniformly before breakfast and before sup-
per, the patient increases it by 2 units every three to 
four days until control is again achieved. If a pattern 
of glycosuria develops in which all the morning 
urines are 3 + to 4 + and the pre-supper urines are 0 
to 1 +, the patient increases the Ultralente® or long-
acting portion of the Lente® mixture. Conversely, if 
late afternoon urines are high in sugar, the patient 
increases the short-acting or Semilente® portion. In 
this way we achieve as good control over the 24-hour 
period as with those who use NPH® twice a day and 
avoid the use of two injections. For this reason we 
have abandoned the use of NPH® in favor of the 
Lentes®. As those of you who follow young children 
know very well, there frequently is no pattern to the 
glycosuria, and levels will go from negative to 4+ . 
One may be guided in such circumstances by daily 
urine volumes and adjust the insulin to keep urine 
volumes in the normal range. 
If acetone appears, the patient is to take regular 
insulin at that time. He or she is asked to take 1/ 5 of 
his or her daily dose of Lente® for moderate or large 
and 1/ 10 for small amounts of acetone. This is re-
peated at subsequent testings if acetone persists. 
If the child becomes ill and is unable to eat or is 
vomiting, the Lente® is omitted and small amounts of 
regular insulin are given. Depending on the nature of 
the problem, the child will be seen in the Emergency 
Room; admitted, or followed at home by phone in-
structions. 
The diet we propose for the diabetic is no differ-
ent from one we propose for the non-diabetic. It con-
sists of a good source of protein as the cornerstone of 
the diet, carbohydrate obtained mainly from 
starches, a drastic reduction in refined sweets, a mix-
ture of predominantly unsaturated and saturated 
fats, and, finally, foods containing adequate rough-
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age, minerals, and vitamins. We allow the patient to 
use his appetite as his guide, warning against gorging 
or excessive snacks, and to use his weight-for-height 
gains as a monitor of his progress. If overweight is or 
becomes a problem in the diabetic, he should be 
approached as a youngster, not a diabetic, with a 
weight problem. I see no reason to single out the 
diabetic in his diet therapy when there is no scientific 
data to suggest this approach is any more harmful to 
him than to his non-diabetic peers. 
We do not attempt to make gross changes in a 
patient's lifestyle. We recommend regular exercise for 
all youngsters, but we do not urge all-out vigorous 
athletics if that is not the child's habit. If exercise can 
be anticipated, the morning dose of insulin is re-
duced. If it cannot, increased carbohydrate intake 
during and after the exercise is required. We explain 
to teen-agers the serious effects of smoking on the 
cardiovascular system and urge them not to begin. 
We explain the hazards of drinking and urge care in 
this area if they do indulge. 
There are a number of special problems we see in 
children and adolescents. 
First of all, the term "brittle" diabetic is fre-
quently used to describe the majority of juvenile dia-
betics. I believe this is too broad a use of the term and 
often reflects only a poor understanding of how to 
manage youngsters whose exercise pattern is unpre-
dictable and whose increased needs with growth are 
not properly met. I would reserve the term for the 
juvenile diabetic who is truly difficult to manage; in 
my experience such patients are few in number and 
all have been teen-age girls under severe emotional 
stress. 
In the adolescent years there is both an increase 
in need for insulin and an increase in binding, with 
insulin resistance of variable degree resulting. Re-
quirements can often rise at an alarming rate to needs 
of 140 to 160 units per day. The periods of increased 
need are variable and unpredictable in their length . 
When the total daily dose reaches 90 to 100 units the 
dosage is split; 2/ 3 is given before breakfast and 1 / 3 
before supper. It is frequently advisable to admit the 
patient to make these adjustments . We admit the 
teen-ager to the Children's Rehabilitation Center 
where both physical and school activities can be pur-
sued so that home conditions are more nearly simu-
lated than on a hospital ward. A schedule is set up in 
which, again, the patient participates. Pre-meal and 
two-hour post-meal blood glucoses are obtained, 
urine volumes are measured, and caloric estimates of 
the food intake that satisfies the patient's appetite in a 
normal manner are made. Urine volumes are col-
lected in the following manner: patient voids and 
discards at 7 AM ; Urine #1 is voidings up to lunch; 
urine #2 up to dinner; urine #3 up to 9 PM, and urine 
#4 overnite to 7 AM. In this manner grams of glu-
cose/ hour spilled in respect to a meal can be 1:,;alcu-
lated. Urine volumes collected periodically at home 
give the diabetic another index of his control. 
True insulin resistance is defined rather arbi-
trarily as a requirement that exceeds 200 units per 
day, occurring in the absence of ketosis, infections, or 
other known stresses. The few cases that have oc-
curred in juvenile diabetics have been predominantly 
among teen-agers 14 to 16 years of age. Most are due 
to increased antibody formation and respond either 
to changing to pork insulin, which is less antigenic 
than beef, or to steroid therapy. We have recently 
reported the very rare occurrence of severe resistance 
to insulin in a 17-year-old gi'rl who does not have 
excessive antibodies either to insulin or to her insulin 
receptors and showed no improvement on steroids.' 
She was resistant to as much as 5,000 units in pork 
regular insulin given subcutaneously, but responded 
normally to a continuous 24-hour infusion of insulin 
and was well regulated in 60 to 70 units pet day. After 
5 months of continuous I. V. insulin she remitted 
spontaneously and is presently regulated on 85 units 
Lente® in the morning and 35 units Lente® before 
supper. Since our report, 5 more females of similar 
age with the same problem have come to our atten-
tion. 
Over-treatment with insulin can of course result 
in hypoglycemia, but it can a lso result in a curious 
and unexplained phenomenon called the Somogyi 
reaction, which usually appears after sudden and ex-
cessive increases in insulin. The reaction is character-
ized by polydipsia and polyuria, sometimes to an 
overwhelming degree. Unlike the patient in acidosis, 
however, the C02 is not elevated though the glucose 
values may be very high. The explanation given by 
Somogyi is that the intense hypoglycemia generated 
by excessive insulin, usually occurring between 2 AM 
and 4 AM, causes a discharge of adrenalin and a swift 
rise in blood glucose to excessive levels. The increased 
glycosuria in the morning and the excessive polyuria 
suggest the need for more insulin, and a vicious circle 
ensues. The patient needs to be hospitalized, taken 
off long-acting insulin, and regulated on regular in-
sulin before returning to Lente®. 
One final problem we encounter, especially in 
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teen-agers, is noncompliance. This must be dealt with 
in a sympathetic yet firm manner. One can only have 
deep feelings of empathy for youths who are strug-
gling to establish their own identity in a world gener-
ally hostile to teen-agers, and who are aware that in 
the not-too-distant future they will be on their own. 
Our approach,2 therefore, is to keep the de-
mands on the patient simple but to work closely with 
him to follow these simple rules: 
1) Double void urine twice a day, test for glu-
cose and acetone, and record results so they 
can be reviewed with the patient. 
2) Take insulin without fail each morning. 
3) Eat a sound diet at regular time intervals and 
in amounts that satisfy appetite and maintain 
normal weight. 
4) Keep regular medical appointments at 3-
month intervals. This provides an opportun-
ity to review the patient's understanding of 
diabetes and its control. 
would now like to turn to a discussion of 
abnormalities in serum proteins, platelets, and red 
blood cells of diabetic subjects discussed at a confer-
ence on Diabetic Microangiopathy held by the Kroc 
Foundation in April, 1976. The conference was ar-
ranged by Dr. Donald McMillan of the Sansum 
Medical Research Foundation and Dr. John Ditzel 
of Aalborg, Denmark, and the papers have appeared 
in the November, 1976 supplement of Diabetes. 3 
The abnormalities I wish to describe may play a 
role in the genesis of diabetic angiopathy or are fac-
tors that reduce tissue delivery of oxygen by hemo-
globin. These mechanisms can lead to tissue hypoxia 
and subsequent tissue damage. 
First, Dr. McMillan, 4 as well as others, describes 
significant increases in serum proteins in diabetics. 
No system of proteins is spared. Studies of newly 
diagnosed diabetics show increases as great as those 
in established diabetics. Abnormalities are independ-
ent of the presence of sequelae of microangiopathy . 
The majority of the proteins elevated in diabetics 
are acute phase reactants: a 1 acid glycoproteins, °'1 
antitrypsin, haptoglobin, ceruloplasmin, C-reactive 
protein, C3C, C4 and C3 activator, and fibrinogen. 
Albumin levels are lower than normal. By direct mea-
surement Dr. McMillan has shown that diabetic se-
rum has a greatly increased viscosity which is due to 
the elevation of these proteins. The abnormal vis-
cosity bears no relation to age, sex, body weight or 
duration or type of treatment of the diabetes. 
Erythrocyte aggregation is markedly increased 
due to the increased fibrinogen level as well as to 
increases in other elongated proteins. Increased 
erythrocyte aggregation has the added effect of en-
hancing the coagulation of blood. 
Platelet aggregation is also increased in diabetics 
in the early stages of the disease as well as later. There 
is a greater sensitivity than normal to aggregating 
agents such as adenosine diphosphate (ADP), epi-
nephrine, and collagen. 
At the same time that intravascular factors are 
leading to the occlusion of small blood vessels, the 
fibrinolytic system, the body's defense against vascu-
lar occlusion, is decreased. This abnormality is more 
pronounced m patients with signs of micro-
angiopathy. 
We have recently made observations on red cell 
membranes in diabetics and have noted an abnormal 
adherence of hemoglobin to the red cell membranes. 5 
Red cell ghosts prepared by the method of 
Dodge were solubilized in 1% sodium dodecycl sul-
fate (SOS), separated by gel electrophoresis and 
stained with Coomassie® Blue (Figure). Increased 
amounts of hemoglobin were noted in the mem-
branes of diabetics, B, C, and D, compared to those 
of a non-diabetic child, A. Dislodging the hemoglo-
bin from red cell ghosts with Tris (hydroxymethyl 
aminomethane ), a nonionic buffer, simultaneously 
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Figure-Membrane proteins of erythrocyte ghosts in I% SDS sepa-
rated by polyacrylamide gel electrophoresis and stained with Coo-
massie"9 Blue. A to D (untreated ghosts): A, normal 12-year-old; B, 
8-year-old on insulin one month; C, top layer of ghosts, pale yellow, 
D, bottom layer, pink, 15-year-old on insulin five years. E and F 
(ghosts extracted with 0.01 M Tris, pH 8.2): E ~A; F ~ B.G to J 
(Tris eluates): G ~ A, H ~ C, I ~ D, and J ~ B. In D note the 
doublet of band 6 and the heavy band of hemoglobin, and the 
appearance of those components in the Tris eluate. The proteins 
are eluated roughly in proportion to the amount of hemoglobin 
adhering to the membrane. 
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removed both peripheral and integral membrane pro-
teins. E and F represent the ghosts after membrane 
bands 4.1 to 4.5, 5, 6, and 7, as well as the hemoglo-
bin. It is suggested that the tightly adhering and 
increased amounts of hemoglobin on diabetic mem-
branes interfere with normal erythrocyte deformabil-
ity because deformability is influenced by the per-
ipheral proteins of the inner aspect of the red cell 
membrane.Normal deformability is essential for nor-
mal blood flow since the diameter of erythrocytes is 
greater than the diameter of the smallest blood ves-
sels through which they must pass. 
Finally there is evidence of disturbance in oxy-
gen transport in diabetics. Rahbar6 originally de-
scribed the abnormal increases of the minor hemo-
globin components Ala, b, and c in diabetic adults. 
We have made a similar report in children. In spite of 
acceptable control of their diabetes, young children, 
and adults as well, have levels that are twice normal. 
The important fact about hemoglobin Ale is that it 
does not react with 2, 3 diphosphoglycerate (2,3 
DPG), thus reducing the ability of hemoglobin Ale 
to yield oxygen to the tissues. Opposing this impair-
ment of oxygen release due to increased levels of Ale, 
Ditzel has found elevated levels of 2,3 DPG but a 
lower than normal P50• Phosphate administration to 
these diabetic children brought their P50 to the level of 
the normal control group. This may be a therapeutic 
approach toward improving oxygenation of diabetic 
tissue that warrants further study. 0 
The legitimate question can now be raised as to 
whether these intra vascular abnormalities are not due 
solely to insulin ·deficiency and therefore simply re-
flect inadequate control of the diabetic state with 
insulin. This may be true. At present we do not know. 
However, in respect to the increases in acute phase 
proteins observed in diabetics, studies of protein syn-
thesis of the perfused rat liver by Miller have revealed 
a very interesting finding. 7 Abnormal alpha cell func-
tion is an integral part of the diabetic state. 8 Gluca-
gon secretion continues during periods of glucose 
plenty and is stimulated by amino acids in the pres-
sure of hyperglycemia. Miller has found that gluca-
gon, either alone or in combination with cortisol, 
stimulates the acute phase proteins including fibrino-
gen. The in vitro effects can be abolished with insulin. 
The possibility thus arises that glucagon excess in a 
setting of insulin deficiency is the initiating factor of 
the sequence of events leading to microvascular oc-
clusion. We have begun a prospective study in our 
young diabetics of the degree of abnormality of 
glucagon secretion and its progression, and the levels 
of acute phase proteins, to determine if a correlation 
exists between them. 
I conclude by paraphrasing a well-known slo-
gan, "We want to find a cure for diabetic micro-
angiopathy before our diabetic children leave adoles-
cence," because success of treatment undoubtedly lies 
in applying it in the trouble-free childhood years. 
The figure is reproduced with permission from Diabetes (25: 
805-930,. 1976). 
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Introduction. 
Elevated titers of natural antibodies have been 
demonstrated in the sera of patients following trans-
plantation.1- 6 These humoral responses were thought 
to be associated with rejection .1 - 10 This concept was 
challenged by investigators whose studies associated 
these responses with infection or with injection of 
heterologous serum. 11 - 15 Nevertheless, the possible 
prognostic significance of these relatively simple tests 
has continued to evoke interest. 
This study was undertaken to compare the hu-
moral responses in three different groups of patients 
with organ transplants in order to evaluate the in-
fluence of duration of the homograft and the atten-
dant immunosuppression. 
Materials and Methods. 
Patient Selection. 
Fifty-eight patients who had received homo-
grafts were selected for study. The patients were di-
vided into three groups: Group 1, 20 patients tested 
prior to transplantation and in the immediate post-
transplant period with a mean duration of follow-up 
of 3.3 months; Group 2, 19 p~tients tested approxi-
mately five to seven years following transplantation 
with a mean follow-up duration of 82.2 months; and 
Group 3, 19 patients tested approximately ten years 
following transplantation with a mean follow-up du-
ration of 118.1 months. 
Correspondence and reprint requests to Dr. Marion Waller, 
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Tests for Anti-Rat Erythrocyte Antibodies ( Het-
erophil Antibodies). 
Rat erythrocytes were washed three times in sa-
line and reconstituted to a 2% suspension. The test 
sera were tested at a 1: 20 dilution and in serial two-
fold dilution for antibody titer. The tubes were al-
lowed to stand at room temperature for 30 mintues, 
spun for 1 minute at 77 g, and read with the naked 
eye. 
Tests for Rheumatoid Factor (A nti-Fc IgG anti-
globulins ). 
The sensitized human cell test (SHC) was used. 
A selected DCe/ DCe test cell was sensitized with 
Ripley serum (highctitered antiDC) diluted 1: 10. The 
Rh-positive cells were sensitized for 60 minutes at 37 
C and then washed three times in sa line. Test sera 
were titrated in saline in 0.1 ml volumes. Titers of 
1: 20 or above were considered positive. 
Tests for Chymotrypsin Agglutinators ( Anti-Fab 
IgG Antiglobulins) Hydrolysis of IgG globulins. 
The IgG globulins of anti-Rh serum (Ripley) 
were isolated by (N H4)2S04 precipitation followed by 
chromatography on diethylaminoethyl (DEAE)-cel-
lulose as previously described.16 Methods of hydro-
lysis of the IgG globulins with chymotrypsin have 
been reported. 17 
Sensitizations. One milliliter (containing 5 mg of 
digested globulin) was added to 0.1 ml of hum an 0, 
DCe/ DCe washed packed cells and sensitized at 37 C 
for one hour. T)le sensitized cells were washed three 
times with sa line and reconstituted to a 2% suspen-
sion. The cells were tested with goat anti-Fe and anti-
Fab (Hyland Laboratories, Los Angeles, California) 
antisera. 
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Methods of testing. Tests for serum agglutinators 
were performed in tubes by adding 0 . 1 ml aliquots of 
the sensitized cells to an equal volume of undiluted 
and serial twofold dilutions of sera to be tested. The 
mixture was allowed to stand at room temperature 
for ten minutes, and then spun for one minute at 77 g 
and read with the naked eye. 
Erythrocyte Sedimentation Rate ( ESR). 
The Westergren method was used to document 
the ESR. The fall of the erythrocytes in millimeters in 
one hour was noted . The normal sedimentation rate 
with this method is 0 to 15 mm for men with an 
average of 4 mm, and 0 to 20 mm for women with an 
average of 5 mm. 
Nitroblue-Tetrazolium Test ( NBT) . 
The NBT test was performed according to the 
modified method of Dorwick'8 on venous blood col-
lected in 4.5 ml vacutainers containing 3.8% sodium 
citrate. The NBT test was performed as soon as pos-
sible after the blood was drawn in order to eliminate 
morphological changes caused by prolonged ex-
posure to the anticoagulant. 
A standard so lution of 0.4% N BT was prepared 
in a IO ml stoppered volumetric flask by dissolving 20 
mg of nitroblue tetrazolium (Grade Ill reagent, 
N6876, Sigma Chemical Co., St. Louis, Missouri) in 
5 ml of sterile 0.85% isotonic saline. To dissolve the 
NBT, the stoppered flask was swirled under hot, run-
ning tap water until the solution beca me clear. This 
solution was then filtered and transferred to a brown 
bottle and stored at 4°C. The solution was stable for 
72 hours . 
Citrated blood, 0.2 ml, was placed in a test tube 
and 0.1 ml of 0.4% NBT was added. The tube was 
mixed by gently shaking, capped and incubated in a 
water bath at 37 C for 30 minutes . The tube was 
removed from the water bath, and one drop of the 
blood-NBT test mixture was added to two pre-
cleaned, labeled glass slides. Special care was taken to 
avoid damage to the white blood cells. The slides 
were air-dried and stained with Wright's stain. The 
stained slides were examined microscopically using 
an oil immersion lens and 100 neutrophils were 
counted. Neutrophils were classified as "NBT-posi-
tive" if they contained any visible formazan deposits . 
Cells that were disrupted or clumped together were 
not counted . The percent of N BT-positive neutro-
phils was reported as 0% to 15% normal and 16% to 
I 00% normal. 
Serum Electrophoresis. 
Serum electrophoresis was performed on cellu-
lose acetate strips, using the Microzone cell, Model 
R-101 (Beckman Instruments , Inc., Fullerton, Cali-
fornia). 
Results. 
Figure I shows the humoral responses of the 20 
patients in Group I during the first five to six months 
following transplantation. The anti-Fab antiglobu-
lins are design ated by dark circles. These antibodies 
a re usually produced as lgG globulins. Only 7 of the 
20 patients showed titers at any time in excess of the 
pretransplant values. Titers below I: 20 are shown as 
lines without a dot dipping below the I: 20 titer level. 
Fluctuations in titer are common. 
The anti -rat erythrocyte antibodies are desig-
nated by open circles. These antibodies are almost 
a lways produced as lgM globulins. Fifty percent (10 
out of 20) of the pa tients showed titers in the post-
transplant period higher than the pretransplant titer. 
Once again, fluctuations in titer are common. There 
I 640 
"° 160 -
eo 
40 
20 
Fig I-Titers of anti-rat erythrocyte antibodies and chymotrypsin 
agg lutin ators in 20 patients in the immediate post-transplant pe-
riod. Open circle: anti-rat erythrocyte: Dark circle: chymotrypsin 
agglut in ato rs. 
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is a tendency for both antibodies to return toward 
pretransplant levels 9 to 12 months after trans-
plantation. 
Although 4 of these 20 patients gave positive 
tests for rheumatoid factors, on ly 3 (patients 2, 7 and 
13) showed titers in excess of the pretransplant val-
ues. Titers were not constant, as is observed in 
chronic rheumatoid arthritis, but fluctuated, cresting 
and then falling, like the other antibodies. The rheu-
matoid factors were invariably made as IgM globu-
lins. 
Modestly elevated titers of anti-sheep eryth-
rocyte antibodies (I : 80) were found in only 2 (pa-
tients 3 and 11) of the 20 patients. 
The blood groups of the 58 patients did not 
significantly influence the serological responses of the 
antibodies tested . 
Figure 2 shows the titers of the anti-rat eryth-
rocyte antibodies (lgM globulins) and the anti-Fab 
antiglobulins (IgG globulins) in the three groups of 
patients in order of increasing duration of the homo-
graft and attendant immunosuppression. The titers of 
the antibodies in Group I were read at three months 
post-transplant. The titers of Groups 2 and 3 were 
performed when they appeared for post-transplant 
check-up. It is apparent from Figure 2 that the num-
ber of patients with significant titers of antibodies 
decreases with duration of the homograft. 
Three of the 38 long-term homograft recipients 
(five to ten years) had positive tests for rheumatoid 
factors . Neither the presence nor the titers of the 
rheumatoid factors were related to the duration of 
the graft. One patient who had shown high titers of 
rheumatoid factors in the past lost this activity 11 
years post-transplant. This patient has developed re-
ticulum cell sarcoma. 
Antibody Titers Anti - rot erythrocyte chymotryps1n 
antibody oggluti notors 
320 6 6 
160 666 • 66 
80 66 t::.t::.t::.t::. 6 
40 66 666 ••• D t::.t::.t::.t::. •• DD 
20 DD 666 • ODDO 666 6 ••• DOD 
•• •• DD •••• OD DO • ••• DODO ( 20 •••• DODO 66 •••• BBBB 6666 •••• ODDO 66D.6 •••• 
Fig 2-lnfluence of duration .of homograft and attendant immuno-
suppression on humoral antibodies in 58 patients. Triangle: mean 
3.3 months: Dark square: mean 82.2 months: Open square: 118.1 
months. 
Relationship of level of gamma globulin to the 
production of humoral antibody. 
Electrophoretic patterns of tlie serum proteins 
were performed on the three groups of patients. The 
patients were divided into two groups, those with 
gamma globulins below 12% and those with gamma 
globulins above 12% (Table I) . In Group I, 5 out of 
the 6 patients with gamma globulin levels below 12% 
made anti-Fab IgG antibodies as did 9 out of the 14 
with gamma globulin levels above 12%. Thus, 70% of 
Group I made these antibodies. However, in Group 
2, on ly 2 out of 11 made these antibodies when the 
level of gamma globulin was below 12%, while 3 out 
of 8 made them when the level of gamma globulin 
was above 12%. In the whole group, 26% made these 
antibodies. In Group 3, none of the 6 patients with 
gamma globulin levels below 12% made these IgG 
antibodies, whi le 5 of the 13 with gamma globulin 
levels above 12% did so. 
A similar pattern is seen for the IgM an ti-rat 
erythrocyte antibodies. There appears to be no effect 
of low levels of gamma globulin in the immediate 
post-transplant group (Group I), but in the long-
term patients, the influence of low levels of gamma 
globulin on both the lgG and lgM antibodies is de-
monstrable. 
Table 2 shows the relationship between the se-
rum creatinine levels and the failure to show humoral 
responses in 37 of the long-term transplant recipients . 
Among the 12 patients with elevated levels of creati-
nine, the incidence of both IgG and IgM antibodies is 
decreased. This decrease in antibody production was 
TABLE I 
a) Relationship of level of gamma globulins to 
/gG antibody production as chymotrypsin agglutinator 
Group 1 * 
Group 2** 
Group 3*** 
< 12% 
5/ 6 
2/ 11 
0/ 6 
> 12% 
9/ 14 
3/ 8 
5/ 13 
Tota l 
14/ 20(70%) 
5/ 19 (26% ) 
5/ 19 (26% ) 
b) Relationship of level of gamma globulins to 
lg M antibody production as anti-rat antibody 
Group 1 * 
Group 2** 
Group 3*** 
< 12% 
6/ 6 
2/ 11 
1/ 6 
* Mean 3.3 months 
•• Mean 82.2 months 
*** Mean 118. I months 
> 12% 
10/ 14 
3/ 8 
6/ 13 
Total 
16/ 20 (80% ) 
5/ 19 (26%) 
7/ 19 (37%) 
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TABLE 2 
Thirty-seven patients with long-term homografts showing a relationship between the serum creatinine level and failure to show humoral responses 
Creatinine levels: 3.1 and above 
0/ 3 
2.6-3.0 
0/ 1 
lgM Antibody Responses 
(anti-rat erythrocyte antibody) 
2.1-2.5 1.5-2.0 
1/ 6 
0.9-1.4 
11 / 25 0/ 2 
Creatinine levels: 3.1 and above 
0/ 3 
2.7-3.0 
0/ 1 
lgG Antibody Responses 
(chymotrypsin agglutinators) 
2.1-2.5 1.5-2.0 
0/ 6 
0.9-1.4 
I 0/ 25 
not related to a significantly higher dose of mainte-
nance immunosuppression . 
Since infection plays a prominent role in patients 
maintained for long periods on immunosuppressive 
agents, the erythrocyte sedimentation rate and the 
NBT test were performed on 37 of the 38 patients in 
Group 2 and 3. The erythrocyte sedimentation test 
was abnormal in 24 of the 37 patients ( 65% ). The 
numerous factors affecting this test, such as anemia 
and dysglobulinemia, lessen the value of this test for 
evaluation of patients with positive tests. The NBT 
test was only positive in 3 of the 37 long-term pa-
tients. Careful review of the discharge summaries 
corresponding to the period at which the test was 
done failed to reveal a reason for these abnormal 
tests. In a further effort to evaluate the significance of 
these positive tests, C3 and C4 levels were determined 
on these patients' sera along with 12 other patients 
who did not show positive NBT tests. The levels of 
C3 and C4 were not significantly altered in the pa-
tients with positive NBT tests. 
Discussion. 
These studies document humoral antibody activ-
ity in the immediate post-transplant period. Rises in 
titer of both IgG antibodies (anti-Fab lgG antiglobu-
lins) and lgM antibodies (anti-rat erythrocyte anti-
bodies) are demonstrable. The antibody rises are usu-
ally inverse to each other, implying that different 
antigens elicit these responses. The antigens on the 
rat erythrocyte are also found on dog and rabbit 
erythrocytes, and related antigens are present on hu-
man B erythrocytes. Thus, the antibodies are termed 
heterophils . McDonald and co-workers19 recently 
studied these antibodies and related the absence of 
the "rat" antigen (HT-A) in the recipients to in-
creased rejection of kidneys from donors with the 
antigen . Their studies have clinical importance and 
help to define complex tissue antigens which will 
receive more attention in the future. 
Rises in titer of the anti-Fab lgG antiglobulins 
0/ 2 
could not be closely associated with rejection. These 
antiglobulins are associated with severe suppurative 
infection in a hospitalized population. 16 In post-
transplant patients, there is a tendency for these an-
tiglobulins to rise when the titers of the anti-rat eryth-
rocyte antibodies are falling, 14 which suggests that 
these are auxiliary immune responses or responses to 
antibody-antigen complexes. 
The dramatic serological responses in the imme-
diate post-transplant period are not repeated in sub-
sequent years. This is probably due to immunosup-
pressivt: therapy. However, we observed no inhibition 
of polymorphonuclear phagocytosis nor depression 
of C3 or C4 levels . On the other hand, laboratory 
tests for infection (sedimentation rate, NBT test) may 
react non specifically, making the diagnosis of occult 
infection difficult. 
As all those interested in transplantation know, 
the greatest drawback in currently available methods 
of immunosuppression is their nonspecificity. This 
fact has stimulated interest in immunological en-
hancement of the kidney graft. Evidence exists that 
kidney grafts in rats can survive by virtue of enhance-
ment.20-25 One approach in humans entailed the pro-
duction of immune sera to leukocyte antigens, fol-
lowed by the hydrolysis of the antibody to remove the 
complement-fixing Fe fragment. The resulting Fab 
fragments were injected into the recipient to bind to 
the antigenic sites on the graft. 26 As discussed pre-
viously, the serum agglutinators are antiglobulins 
which have specificity for Fab fragments following 
hydrolysis. These antiglobulins are naturally occur-
ring IgG globulins commonly found in low titer. 
However, the serum agglutinators (named homoreac-
tant in rabbits) are not apparently stimulated by the 
injection of Fab fragments, 27 but once stimulated, 
their ability to reconstitute the biological potential of 
the Fab fragment has been established. 28 Therefore, it 
would be essential to test the recipient for these anti-
globulins prior to the injection of the Fab fragments . 
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In any case, the role of the anti-Fab antiglobulins 
must be considered when Fab fragments are used to 
achieve blocking of the antigenic sites of a homo-
graft. 
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BOOK REVIEW 
Marks, Geoffrey and Beatty, William K. Epidemics. 
New York, Scribner's, xii, 323, illus. 1976. $9.95. 
McNeil!, William H. Plagues and Peoples. Garden 
City, New York, Doubleday, viii, 369, 1976. $10.00. 
Epidemics, like the poor, a re always with us; the 
rapid rise a nd the equally rapid fall of swine influenza 
attest this statement. The publication of two books 
with the common theme of epidemic disease, but with 
different approaches to it , is therefore welcome and 
timely, particularly as there are no authoritative 
books on this subject in print. 
Both book s rely on established secon dary 
so urces an d especially on one nineteenth century 
monument of scholarship: August H irsch 's Hand-
book of Geographical and Historical Pathology'; both 
books describe the chronology of epidemic disease on 
a worldwide bas is ; both books a re primarily written 
for the lay man; and both books contain extensive 
reference notes. Where they differ is in their correla-
tion of infectious disease and social history. This , of 
course, is not surprising as Messrs. Marks and Beatty 
are a medical journalist and medical bibliographer 
respectively, while Dr. McNeil! is a social hi storian. 
Epidemics presents a broad view of the world-
wide pattern of infectious disease, ranging from bibli-
cal plagues to recent influenza pandemics. There is no 
acknowledgement of medical consultation in the 
preface, and this may acco unt for some of the book 's 
shortcomings, one of which is the absence of com-
ment on the secular changes in the virulence of 
st reptococcal infections . The most glaring omission is 
rubella , both as an infectious di sease and as the cause 
of birth defects. Rubell a would have been an ideal 
foundation on which to build the last chapter of the 
book, entitled "The Continuing Scene, " which at-
tempts to "provide bridges" between the old and the 
new epidemiology. One "bridge" used-"Dog Bites: 
An Unrecognized Epidemic"-is somewhat specious; 
another, lead poisoning, lacks bibliographical sup-
port, ignoring both the Baltimore epidemic of 1932 
(probably the best example of a modern epidemic of 
plumbism 2 ) and the possible role of lead poisoning in 
the fall of Rome.3 There is a lso in this chapter a 
MCV QUARTERLY 13( 1): 37-39, 1977 
misunderstanding of today's epidemiological ap-
proach to the chronic non-infectious diseases , for 
example, "The term epidemic is currently used 
loosely in such statements as 'we a re faced with an 
epidemic of heart disease ... '" As Morris has so 
frequently pointed out, there is indeed a modern epi-
demic of heart disease, to which may be added lung 
cancer and many more syndromes; in fact, modern 
epidemiological research into chronic disease control 
is a direct extension of the methods used in epidemic 
infectious disease investigations.4 
Two points of historical interest are missed or 
confused. First, the Black Assizes in England in the 
sixteenth and seventeenth centuries were six in num-
ber , the most dramatic by far being at the old Bailey 
in London, where the Lord Mayor of London was 
infected with, an d later died from , typhus .5 Second , 
the account of John Snow's cl assic investigation of 
cholera in Soho is misrepresented , perhaps because it 
is based on a secondary source paper in Scientific 
American instead of the readily avai lable original 
work by Snow.6 The famous Broad Street Pump epi-
demic occurred in 1854, and not in 1849, the year in 
which Snow fir st published his theory of cholera 
propagation. Although Messrs . Mark s's and Beatty 's 
acco unt does not categorically state tha t the epidemic 
occurred in 1849, neither does it make it clear that it 
occurred in 1854; surprisingly , this confusion has ap-
peared several times in epidemiological papers during 
the past ten years, most notably in the first edition of 
MacM ahon' s Epidemiology (the date was corrected 
to 1854 in the second edition).7 These are, however, 
minor omissions and the book on the whole is accu-
rate and readable, as one would expect from its a u-
thors' credentials. There is a lingering impression that 
Epidemics was written from a previously compiled list 
of references rather tha n from primary observations 
which were verified and added to as the book was 
written. This must be a fairly common ploy of writing 
in these "publish or perish" days, the references being 
used as the point of depa rture rather than the text 
an d context of the paper. 
In summary, Epidemics serves its purpose as an 
interesting, mostly dependable , account of the evolu-
tion and ravages of epidemic infectious disease, with 
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the authors' comments liberally supported by quota-
tions from contemporary documents. Its content is 
mainly descriptive, although it does not entirely ig-
nore the social consequences of disease outbreaks. 
Plagues and Peoples is a more scholarly work, 
which one would expect from Dr. McNeill, who won 
the National Book Award for History in 1964 with 
his book, The Rise of the West: A History of the 
Human Community. 8 Dr. McNeill's book documents 
and explains the effect of epidemic disease on the 
structure and evolution of civilization, both through 
the microcosm of microorganisms and the mac-
rocosm of man's military machinations. The theme of 
war and disease has been dealt with before by Prinz-
ing9 and Major,10 but neither of their works presents 
the correlation of epidemics and social change which 
is the basis of Plagues and Peoples. Unlike Messrs. 
Marks and Beatty, Dr. McNeill consulted physicians 
and medical historians in writing his book, and his 
accurate medical facts are supported by 55 pages of 
references and notes. Perhaps a brief description of 
Pavlovsky's work in landscape epidemiology11 would 
have been welcome in the final pages of the book, 
particularly as it is the antithesis of the Australian 
experience with myxomatosis, a topic used several 
times to illustrate man's ecological blunders. As in all 
works of this type, speculation on early epidemics is 
replaced by the increasing certainty of documenta-
tion and diagnoses after the Black Death; this makes 
the later epidemics more vivid and interesting to the 
reader, and of more value to the interpreting social 
historian. 
Neither book contains references to several clas-
sical epidemiological texts which should not be ig-
nored in any survey of epidemic disease; the works of 
Murchison5 and Drake12 particularly come to mind. 
It is surprising, too, to see no reference to America's 
greatest work on cholera, usually ascribed, wrongly, 
to Woodworth .13 The modern works of Ack-
erknecht14 and Henschen 15 might have been men-
tioned, as might the specialized studies of Bell'6 and 
Ashburn. 17 The social aspects of disease summarized 
in Zinsser18 could also have received more recogni-
tion, and Hare's Pomp and Pestilence'9 might have 
been noted as an introduction to the theme of Plagues 
and Peoples. Finally, any work describing the world 
picture of epidemics should contain maps to facilitate 
the reader's understanding of the geographical and 
temporal spread of disease; the only map in either 
volume is one on the Black Death in Dr. McNeill's 
book. The recent resurgence of interest in medical 
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geography might have been used and some of the 
many maps in existence copied or modified, if new 
maps were too costly to prepare.20 A good example of 
the use of maps to supplement the text is Siegfried's 
Germs and ldeas, 21 in itself a pioneering precursor of 
Plagues and Peoples. 
These two books complement each other; the 
descriptive content of Epidemics is expanded in 
Plagues and Peoples into a fascinating portrait of the 
interaction of civilization and disease, a subject al-
ready dealt with by Sigerist.22 What McNeill has done 
for communities needs to be done for individuals, 
although a book by L'Etang23 has taken the first 
step towards relating disease to the decisions affecting 
history made by a single man or woman. Should this 
study be made, one could not wish for a more schol-
arly work than Plagues and Peoples, presented per-
haps in the familiar style of Epidemics. 
F.J.S. 
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A service to medical education from A. H. Robins: '"'~ Excerpted from Volume 2 oflheG.I. 
Sen es 
on physical examination 
of the abdomen: 
Normally palpable organs: 
the edge of the li)(er descending, 
on inspiration, below the costal 
margin (AJ ; the lower pole of the 
right kidney (BJ; the abdominal 
aorta (CJ; the descending colon 
and the sigmoid (DJ; the ascend-
ing colon (EJ; and occasionally 
the bladder (though rising of 
this organ beyond the pubis 
does not necessarily indicate 
disease). 
Impossible to outline, unless 
diseased, d istended or enlarged: 
the gallbladder, pancreas, 
stomach, small intestine, trans-
verse colon and spleen. 
The A H Robins G I Series consists of six book- 1 :I lets, designed to provide a quick, yet comprehen- I }' sive review of basic procedures and practices 1n  1\ 
G .I. m edic ine - w ith partic ula r emphasis on the i 
physical examination as performed 1n the office or \., ::::..., 
at bedside. If you have teaching respons1b1llt1es, 
limited quantities are available: Part 1 - Inspection, ·--... 
Pa rt 2 - Palpation, Part 3-Percussion. Part 4 - Auscultation, Part 5 -
Abdominal Pain and Part 6 - D ifferential D iagnosis of Abdominal 
Disorders. Write to : The Medical Department , A H . Robins Company, 
1407 Cummings Drive. Richmond , Virginia 23220 . 
A service to medical education from A. H. Robins: 1--~-!,'·.·1·.·~. ~ Excerpted from Volume 2 oftheG.I. 
Sen es 
on physical examination 
of the abdomen 
Normally palpable organs: 
the edge of the li'ier descending, 
on inspiration, below the costal 
margin (A); the lower pole of the 
right kidney (8); the abdominal 
aorta (C); the descending colon 
and the sigmoid (0) ; the ascend-
ing colon (E); and occasionally 
the bladder (though rising of 
this organ beyond the pubis 
does not necessarily indicate 
disease). 
Impossible to outline, unless 
diseased, distended or enlarged: 
the gallbladder, panc reas, 
stomach, small intestine, trans-
verse colon and spleen. 
The A. H . Robins G .I. Series consists of six book-
lets, designed to provide a quick, yet comprehen- \ · 1 
sive review of basic procedures and practices in 
G .I. medic ine - with particular emphasis on the t 
physical examination as performed in the office o r ~' · ~ 
at bedside. If yo u have teaching responsibilities ' ...... 
limited quantities are available• Part 1 - Inspection, 
Part 2 - Palpation, Part 3 - Percussion, Part 4 -Ausc ultation, Part 5 -
Abdom ina l Pain and Part 6-Differential Diagnosis o f Abdominal 
Disorders. Write to• The Medical Departm ent. A H. Robins Company, 
1407 Cummings Drive. Richmond . Virginia 23220 
each tablet. 
capsule or 5 ml 
(tsp ) of elixir 
(23% alcohol) 
Phenobarbital (V.. gr) 16.2 mg 
(warning; may be habit forming) 
Hyoscyamine sulfate o. 1037 mg 
Atropine sulfate 0.01 94 mg 
Hyoscine hydrobromide 0.0065 mg 
each 
Donnatal 
No. 2 Tablet 
[ Y2 gr) 32.4 mg 
0.1037 mg 
0.01 94 mg 
0.0065mg 
Indications: Based on a review of this drug by the NAS/ NRC 
and/ or other information. FDA has classified the following indica-
tions as possibly effective: adjunctive therapy in the treatment of 
peptic ulcer; the treatment of the irritable bcwel syndrome (irritable 
colon, spastic colon, mucous colitis) and acute enterocolitis. · 
Final classification of the less-than-effective indications requires 
further investigation 
Brief summary. Contraindicated in patients with glaucoma, renal or 
hepatic disease, obstructive uropathy (for example, bladder neck 
11 H obstruction due to prostatic hypertrophy) or a hypersensitivity to any of 
n• ·ROBINS the ingredients. Blurred vision, dry mouth, difficult urination, and 
flushing or dryness of the skin may occur at higher dosage levels, rarely A H. Robins Company, Richmond, Virginia 23220 at the usual dosage. 
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